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ABSTRACT
Since atherosclerosis is considered an inflammatory disease, there has been exten-
sive research to determine whether microbial infections possibly contribute and 
maintain this inflammatory response.  Chlamydia pneumoniae, a common causative 
agent of respiratory tract infections, was associated with cardiovascular diseases as 
early as the late 80´s.  C. pneumoniae is a gram-negative bacterium which resembles 
viruses in terms of obligate intracellular growth.  C. pneumoniae is able to infect 
several cell types, including circulatory monocytes, and by using monocytes as a 
vehicle, C. pneumoniae can disseminate from the lungs into extrapulmonary sites, 
including the subendothelial space of the arterial wall.  In addition to inflammation, 
lesion development in the arterial wall requires macrophage transformation to lipid-
laden foam cells in the presence of an atherogenic cholesterol source like low-
density lipoprotein (LDL) cholesterol.  Chronic C. pneumoniae infection has been 
demonstrated to change lipoprotein distribution towards a pro-atherogenic lipid 
profile with increased VLDL and LDL and decreased high-density lipoprotein 
(HDL).  Statins, a class of cholesterol drugs currently in wide use, not only decrease 
LDL and increase HDL cholesterol levels but also have an anti-inflammatory effect 
and are thus highly cardioprotective.    
The present study investigated the effect of acute C. pneumoniae infection on 
serum lipid metabolism in mice.  In addition, the effect of pravastatin treatment on 
C. pneumoniae infection and the infection-induced pulmonary inflammatory re-
sponse and changes in serum lipid metabolism were investigated in an NIH/S mouse 
model during regular chow and a high fat diet.  The second aim was to develop a 
new diagnostic method for C. pneumoniae infection and apply the method to ana-
lyze clinical samples. 
In NIH/S mice with regular chow, acute C. pneumoniae infection had mild ef-
fects on serum lipids and caused a transient yet significant increase in serum triglyc-
erides and a decrease in lecithin-cholesterol acyltransferase (LCAT) activity.  How-
ever, these changes, if prolonged during chronic C. pneumoniae infection, may im-
pair lipoprotein metabolism and produce a pro-atherogenic lipid profile.  One unex-
pected observation was that pravastatin treatment during a high fat diet induced a 
significant increase primarily in triglycerides but not in cholesterol both in C. pneumo-
niae-infected and uninfected mice. Pravastatin accelerated the pulmonary inflamma-
tory response to the C. pneumoniae infection, but had no effect on infection load.  
Since NIH/S mice normally have an antiatherogenic lipid profile with high HDL and 
low apoB-containing lipoproteins (VLDL, LDL), mouse strains or other animal mod-
els with a more humanized lipid profile (high LDL, low HDL) should be used in order 
to detect the favorable effects of statins on serum lipid levels.  Since anti-inflammatory 
and cholesterol-lowering capacities differ among various statins, other statins might be 
more effective during C. pneumoniae infection.
 To develop a sensitive and specific enzymeimmunoassay (EIA) method for the 
measurement of serum chlamydial lipopolysaccharide (cLPS) concentration, a novel 
approach was employed.  LPS was dissociated and captured from lipoprotein and 
immune complexes in serum by lipopolysaccharide binding protein (LBP) in the 
presence of an octylglucoside detergent.  The method was applied to the quantitation 
of cLPS in the sera of patients with acute coronary syndrome (ACS) and their con-
trols.  Significantly higher cLPS concentrations and prevalence were found in ACS 
patients compared to their controls.  During ACS, the highest cLPS levels were 
found within 48 hours and the cLPS levels rapidly decreased as early as one week 
after the event.  cLPS levels were significantly higher in acute myocardial infarction 
(AMI) patients as compared to patients with unstable angina (UA) at the time of 
hospitalization.  In addition, a significant correlation was demonstrated between 
serum cLPS and highly sensitive C-reactive protein (hsCRP) levels throughout the 
one-year follow-up period in ACS patients.  Our data not only strengthen the asso-
ciation between C. pneumoniae infection and cardiovascular disease but also high-
light the role of C. pneumoniae LPS in the inflammatory process during acute coro-
nary syndrome. 
Keywords: Chlamydia pneumoniae, NIH/S mouse model, lipid metabolism, chronic 
infection, acute coronary syndrome, lipopolysaccharide, highly sensitive C-reactive 
protein 
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TIIVISTELMÄ 
Koska ateroskleroosia pidetään nykyään tulehdussairautena, viime vuosien aikana 
on tutkittu voivatko mikrobi-infektiot aiheuttaa ja ylläpitää tätä tulehdusreaktiota. 
Chlamydia pneumoniae, keuhkoklamydia, on yleinen hengitystieinfektioiden aiheut-
taja, joka jo 1980-luvun lopulla yhdistettiin yhdeksi sydän- ja verisuonitautien riski-
tekijäksi.  Keuhkoklamydia on gram-negatiivinen bakteeri, joka virusten tavoin 
lisääntyy ainoastaan elävien solujen sisällä.  Keuhkoklamydia infektoi useita erilai-
sia solutyyppejä ja sen leviäminen keuhkojen ulkopuolelle, kuten valtimon seinä-
mään, tapahtuu infektoitujen monosyyttien välityksellä.  Tulehduksen lisäksi valti-
movaurion muodostuminen edellyttää makrofagien muuntumista kolesterolirikkaiksi 
vaahtosoluiksi aterogeenisen kolesterolilähteen, LDL:n, läsnäollessa.  Kroonisen 
keuhkoklamydiainfektion on osoitettu liittyvän verenkierron pro-aterogeeniseen 
lipidiprofiiliin mikä ilmenee kohonneena LDL- ja alentuneena HDL-
kolesterolipitoisuutena.  Nykyisin laajasti käytetyt kolesterolilääkkeet, statiinit, eivät 
ainoastaan laske LDL kolesterolia ja nosta HDL tasoja, vaan ovat myös tulehdusta 
estäviä ja suojaavat siten tehokkaasti sydän- ja verisuonitaudeilta.         
Tässä tutkimuksessa analysoitiin akuutin keuhkoklamydiainfektion vaikutusta 
seerumin rasva-aineenvaihduntaan.  Lisäksi selvitettiin pravastatiinin vaikutusta 
keuhkoklamydiainfektioon sekä infektion indusoimaan keuhkojen tulehdusvastee-
seen sekä seerumin lipidimuutoksiin normaalilla ja rasvapitoisella rehulla ruokituilla 
NIH/S hiirillä.  Tarkoituksena oli myös kehittää uusi menetelmä keuhkoklamydiain-
fektion diagnotiikkaan ja soveltaa tätä menetelmää potilasaineistojen tutkimiseen.   
Keuhkoklamydiainfektio aiheutti lieviä muutoksia seerumin rasvatasoihin 
NIH/S hiirillä: havaittiin vain ohimenevä mutta merkittävä triglyseriditasojen nousu 
ja lesitiini-kolesteroli asyylitransferaasientsyymin (LCAT) aktiivisuuden lasku.  Jos 
nämä muutokset pitkittyvät kroonisen keuhkoklamydiainfektion aikana, ne voivat 
häiritä lipoproteiinien aineenvaihduntaa ja johtaa sydäntauteja edistävän pro-
aterogeenisen lipidiprofiilin syntyyn verenkierrossa.    Yllättävä havainto oli, että 
pravastatiinihoito rasvaruokituilla hiirillä aiheutti merkittävän nousun triglyserideis-
sä mutta ei kolesterolissa.  Samantyyppinen vaste nähtiin pravastatiinihoidetuilla 
hiirillä keuhkoklamydiainfektion aikana.   Pravastatiinihoito aikaisti, mutta ei vähen-
tänyt keuhkojen tulehdusvastetta.  Koska NIH/S hiirillä on sydäntaudeilta suojaava 
rasvaprofiili, korkea HDL ja matalat apoB-lipoproteiinit (LDL, VLDL), statiinihoi-
don suotuisat vaikutukset saattaisivat tulla esiin hiirillä tai muilla eläimillä, joilla on 
“ihmistyyppinen” seerumin lipoproteiiniprofiili (korkea LDL, matala HDL).  Koska 
tulehdusta estävä ja kolesterolia alentava vaikutus vaihtelee eri statiinien välillä, 
toiset statiinit saattaisivat olla tehokkaampia.      
Sovelsimme uutta lähestymistapaa kehittäessämme herkkää ja spesifistä ent-
syymi-immunologista määritysmenetelmää klamydian lipopolysakkaridin (cLPS) 
mittaamiseen seerumista.  LPS irroitettiin seerumin proteiinikomplekseista lipopo-
lysakkaridia sitovan proteiinin (LBP) avulla oktyyliglukosidi-detergentin läsnäolles-
sa.  Kun menetelmää sovellettiin klamydian LPS:n mittaamiseen akuutti koronaa-
risyndroomapotilailta ja heidän kontrolleiltaan, havaittiin että potilaiden seerumeissa 
oli kontrolleja useammin klamydian LPS:a ja lisäksi LPS:n pitoisuus potilailla oli 
myös merkittävästi korkeampi kuin kontrolleilla.  Korkeimmat klamydian LPS-
pitoisuudet havaittiin 48 tunnin kuluessa akuutin sydänkohtauksen alkamisesta, ja 
LPS-tasot olivat jo viikon kuluttua tapahtumasta laskeneet merkittävästi.  Sairaalaan 
tulohetkellä klamydian LPS-taso oli merkittävästi korkeampi akuutin sydäninfarktin 
saaneilla kuin epästabiilia rintakipua sairastavilla potilailla.  Lisäksi klamydian 
LPS:n tasot korreloivat merkittävästi herkän C-reaktiivisen proteiinin tasoihin 
(hsCRP) läpi vuoden kestävän seuranta-ajan.  Nämä tulokset eivät ainoastaan vah-
vista keuhkoklamydiainfektion yhteyttä sydäntauteihin, vaan ne myös viittaavat 
siihen, että klamydia-LPS osaltaan aiheuttaa akuuttiin sydänkohtaukseen liittyvän 
tulehdusreaktion.  
Avainsanat: keuhkoklamydia, hiirimalli, rasva-aineenvaihdunta, krooninen infektio, 
akuutti koronaarisyndrooma, lipopolysakkaridi, herkkä C-reaktiivinen proteiini 
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3ABBREVIATIONS 
ABCA1 ATP-binding cassette transporter A1 
ACS  acute coronary syndrome 
AMI acute myocardial infarction 
apo apolipoprotein 
APOE KO apolipoprotein E knockout  
APR acute phase response 
ATP adenosine triphosphate 
AUC area under the curve 
BPI bacteridical permeability increasing protein 
CETP cholesterol ester transfer protein 
CF complement fixation 
CHD coronary heart disease 
CM chylomicron 
COMC chlamydial outer membrane complex 
EB elementary body 
EIA enzyme immunoassay 
EM electron microscopy 
HDL high density lipoprotein 
HL hepatic lipase 
HMG-CoA  3-hydroxy-3-methylglutaryl coenzyme A 
hsCRP highly sensitive C-reactive protein 
Hsp  heat schock protein 
ICC immunocytochemistry 
IDL intermediate density lipoprotein 
IFN interferon 
IFU inclusion forming unit 
IL interleukin 
IM immunofluorescence 
Inc inclusion membrane protein 
iNOS inducible nitric oxid synthase 
kDa kilodalton  
KDO 3-deoxy-D-manno-octulosonate 
4LBP lipopolysaccharide binding protein 
LCAT lecithin-cholesterol aclyltransferase 
LDL low density lipoprotein 
LDLR LDL receptor 
LDLR KO low density lipoprotein receptor knockout 
LPL lipoprotein lipase 
LPS lipopolysaccharide 
LRP LDL-receptor related protein 
mCD14 membrane bound CD14 
MCP monocyte chemoattractant protein 
MIF microimmunofluorescence 
MOMP major outer membrane protein 
NacGlc N-acetyl-D-glucosamine 
NF-κβ nuclear factor κβ 
NIH mouse National Institute of Health mouse 
OM outer membrane 
Omp Outer membrane protein 
PAF-AH platelet activating factor acetylhydrolase 
PBMC peripheral blood mononuclear cell 
PCR polymerase chain reaction 
p.i. post infection 
PLTP phospholipid transfer protein 
Pmp polymorphic membrane protein 
PON paraoxonase 
RB reticulate body 
ROC-curve receiver operating characteristic curve 
SAA serum amyloid A 
sCD14 soluble CD14 
SREBP sterol regulatory binding protein 
TLR Toll-like receptor 
TNFα tumor necrosis factor α 
TTS type III secretion 
VLDL very low density lipoprotein 
VSMC vascular smooth muscle cells 
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61 INTRODUCTION
Atherosclerosis is a leading cause of mortality in Western industrialized countries.  
Hypertension, hypercholesterolemia [high low density lipoprotein (LDL) and low high 
density lipoprotein (HDL) cholesterol levels], cigarette smoking, diabetes, obesity, 
physical inactivity (Braunwald, 1997), age (Gordon et al., 1977; Uren et al., 1995), 
psychosocial (Eaker et al., 1992) and genetic (Schildkraut et al., 1989) factors as well 
as male gender (Jousilahti et al., 1999) are the well-established risk factors for coro-
nary heart disease (CHD).  However, all CHD cases cannot be explained by the pre-
ceding risk factors only.  Since infection and inflammation have been appreciated as 
relevant underlying risk factors for atherosclerosis during the past decade (Ross, 
1999), interest in the search for candidate pathogens has increased.   
Certain pathogens, such as Chlamydia pneumoniae, cytomegalovirus, herpes 
simplex virus, Porphyromonas gingivalis, and Helicobacter pylori, are currently 
linked with the pathogenesis of CHD and atherosclerosis (Fong, 2000; Leinonen et 
al., 2002; Saikku et al., 1988).  Among these agents, the role of C. pneumoniae in 
atherosclerotic diseases has been studied most intensively and the association has 
been verified seroepidemiologically, by the presence of viable organisms in the le-
sions as well as by animal and some clinical studies.  The earliest findings were 
based on the presence of seroresponse in acute myocardial infarction (AMI) and 
higher C. pneumoniae antibody titers in CHD patients than in their controls (Saikku
et al., 1988), and, at present, there is mounting evidence linking C. pneumoniae
infection with atherosclerosis (Grayston et al., 1995; Kuo et al., 1993a; Kuo et al.,
1995a; Kuo et al., 1993b; Muhlestein et al., 1996; Ong et al., 1996; Ramirez, 1996; 
Shor et al., 1992). The presence of C. pneumoniae has been demonstrated both in 
circulating monocytes and within atherosclerotic lesions (Belland et al., 2004) and 
even viable Chlamydiae have been isolated from the atherosclerotic plaques and 
abdominal aortic aneurysms (Johnston et al., 2001; Karlsson et al., 2000; Maass et 
al., 1998; Ramirez, 1996). 
C. pneumoniae, a small, obligatory intracellular gram-negative bacterium is one 
of the most common respiratory pathogens worldwide (Grayston et al., 1990).  Se-
roepidemiological surveys indicate that about 50 % of middle-aged adults have C.
pneumoniae antibodies and that reinfections are common (Grayston et al., 1990).  
The clinical features of infections that are transmitted via airways from person to 
person vary from mild, even asympomatic upper respiratory tract infections to se-
vere bronchitis and pneumonia (Saikku et al., 1985; Thom et al., 1990).  As with all 
chlamydial species, C. pneumoniae has a tendency to cause persistent and chronic 
infections, which are suggested to connive in the development of reactive arthritis 
7(Braun et al., 1994), erythema nodosum (Erntell et al., 1989; Saikku et al., 1985), 
sarcoidosis (Ekman et al., 1993a; Grönhagen-Riska et al., 1988), asthma (Hahn, 
1992), chronic obstructive pulmonary disease (Von Hertzen et al., 1997) and athero-
sclerosis (Belland et al., 2004; Leinonen et al., 2002). 
Because of serious implications for a variety of diseases, eradication of C. pneu-
moniae infection has become very important.  However, screening for C. pneumoniae 
infection requires reliable diagnostic methods.  Currently, laboratory diagnosis of C.
pneumoniae infection is based on serology, cultivation or demonstration of the pres-
ence of the organism by nucleic acid amplification tests such as polymerase chain 
reaction (PCR).  However, serology is only an indirect indicator of current or past 
infection.  Representative samples can be impossible to obtain from the diseased tis-
sues, e.g. from atherosclerotic plaques for the demonstration of the organisms.  In 
addition, the methods may lack specificity (serology), sensitivity (culture) or both 
(PCR).  Therefore, there exists an urgent need for new sensitive and specific diagnos-
tic tools especially for the diagnosis of chronic C. pneumoniae infections.
82 REVIEW OF THE LITERATURE 
2.1 Chlamydia pneumoniae
2.1.1   Taxonomy 
Chlamydia pneumoniae is a member of genus Chlamydia, which belongs to the family 
Chlamydiaceae in the order Chlamydiales (Moulder et al., 1984). C. pneumoniae,
first considered to be an unusual C. psittaci strain called TWAR (Saikku et al., 1985), 
was identified as a third chlamydial species in the late 1980s (Grayston et al., 1990) 
and was followed by C. pecorum, a pathogen of ruminants (Fukushi et al., 1992). 
Based on phylogenetic analyses of the 16S and 23S rRNA genes, a new taxo-
nomic classification was recommended in 1999 (Everett et al., 1999).  Accordingly, 
the genus Chlamydia should be broken into two genera, Chlamydia and Chlamydo-
phila (Table 1).  Furthermore, three novel families, Parachlamydiaceae, Simniaceae 
and Waddliaceae, were suggested to be included in the genus Chlamydia (Everett et 
al., 1999).  Nonetheless, the new taxonomy is still under debate and lacks consensus 
among chlamydial authorities (Schachter et al., 2001).   
Table 1.  Proposal for Chlamydial taxonomy (modified from Everett et al., 1999). 
Genus Species Host Route of entry 
Chlamydia C. trachomatis Human Pharynx, eye, genital, rectal 
 C. suis Swine Pharynx 
 C. muridarum Mouse, hamster Pharynx, genital 
Chlamydophila C. psittaci Bird Pharynx, eye, genital 
 C. pneumoniae Human Pharynx, eye 
 C. pecorum Mammals Oral 
 C. felis Cat Pharynx, eye, genital 
 C. caviae Guinea pig Pharynx, eye, genital, urethral 
 C. abortus Mammals Oral, genital 
92.1.2   History 
Chlamydial diseases have been known since antiquity (Oriel, 1994), although the 
pathogen itself remained mysterious for a long time.  The earliest chlamydial spe-
cies, C. trachomatis, perceived as a trachoma agent in 1907, was first considered 
protozoa and thus conferred the name Chlamydozoaceae (Ward, 1983).  Based on 
the small size and poor growth in culture media Chlamydia was later categorized as 
an unusual virus.  In 1930s, Bedson & Bland described a second chlamydial species, 
C. psittaci, as an “obligate intracellular bacteria-like parasite”, an assumption that 
was not attested until the 1960s. 
C. pneumoniae was originally discovered in the 1940s by Joseph Smadel, who 
described atypical psittacosis in patients without bird contact.  This “humanized 
strain of virus” appeared to disseminate from human to human via the respiratory 
route (Smadel, 1943).  Several epidemics of this type as arnithosis or “para-
ornithosis” were described from Scandinavia in the 1950’s (Jansson, 1960).  How-
ever, C. pneumoniae needed to be “re-discovered” in the 1980’s (Saikku et al.,
1985) and was named TWAR after two laboratory isolates TW-183 (isolated from 
the child eye in Taiwan in 1965) and AR-39 (isolated from a throat swab of a stu-
dent in USA in 1983) (Grayston et al., 1986).  Genetically, C. pneumoniae shares 
less than 10 % sequence identity with other chlamydial species (Grayston, 1989).   
2.1.3   Structure 
Chlamydial envelope components play a crucial role in the infection process, i.e. protect-
ing extracellular elementary bodies (EBs) from the action of antibodies, involvement in 
the attachment and uptake of the EBs to the host cell, and presumably also preventing 
lysosomal fusion after EB entry into the host cell (Longbottom et al., 1998).   
Both extra and intracellular chlamydial forms have a double cell membrane, 
which is peculiar to all gram-negative bacteria.  The inter-membrane space lacks 
muramic acid (Barbour et al., 1982; Fox et al., 1990; Garrett et al., 1974), which is 
an essential polymer of the peptidoglycan layer in the bacterial cell wall.  The rigid-
ity of the cell wall is chiefly maintained by disulfide-bridges in the cysteine-rich 
major outer membrane protein (MOMP) (Campbell et al., 1990), which covers about 
60 % of the chlamydial outer membrane (OM) mass (Caldwell et al., 1981).  C.
pneumoniae MOMP is also surface-exposed and immunogenic; it is approximately 
42 kilodalton (kDa) in size (Campbell et al., 1990; Knudsen et al., 1999; Wolf et al., 
2001).  Serovar-, subspecies and species-specific differences in C. trachomatis
10
MOMP have been identified (Conlan et al., 1988; Stephens et al., 1988; Zhang et al., 
1989), whereas C. pneumoniae MOMP appear constant (Perez Melgosa et al., 1991).   
In Chlamydiae, MOMP is a major protein component in the chlamydial outer mem-
brane complex (COMC).   COMC also contains other cysteine-rich proteins, outer 
membrane proteins (Omps).  Omp2 and Omp3 in C. psittaci are not surface-exposed 
(Everett et al., 1995), while Omp 4 and Omp 5 have been localized by immunofluores-
cence (IM) microscopy on the surface of C. pneumoniae (Knudsen et al., 1999).   
Quite recently, a new family of chlamydial proteins, polymorphic membrane 
proteins (Pmps), was indentified in the chlamydial genome.  Even 21 Pmps have 
been found in C. pneumoniae but only 9 Pmp genes in C. trachomatis genome, re-
spectively (Kalman et al., 1999).  The signal peptide sequence indicates the localiza-
tion of most Pmps on the outer membrane in C. pneumoniae (Pedersen et al., 2001).  
The definite function of Pmps is not known, but they have been proposed to act as 
primary mediators in pathogen-host cell interactions (Christiansen et al., 1999). 
Heat schock proteins, Hsps, are conserved proteins among prokaryotes and eu-
karyotes and their expression can be induced by stress or injury, like infections 
(Kaufmann, 1990).  Chlamydia express Hsps under stress conditions, for instance 
during a deficiency of tryptophan, the amino acid that Chlamydia is unable to syn-
thesize (Beatty et al., 1994a; Beatty et al., 1994b).  To date, three chlamydial Hsps, 
cHsp10, cHsp60 and cHsp70, have been characterized (LaVerda et al., 1997; Morri-
son et al., 1989; Raulston et al., 1993).  Chlamydial Hsp60, produced during the 
growth cycle and released from inclusions during the host cell lysis, induces the 
production of inflammatory mediators by vascular smooth muscle cells, endothelial 
cells and macrophages (Kol et al., 1999; Kol et al., 1998).  A host immune response 
to microbial Hsp60 may trigger an autoimmune response against human Hsp60 and 
eventually speed up the progression of atherosclerosis (Kol et al., 1998; Mosorin et 
al., 2000; Wick et al., 2001).    
There are also proteins localized solely in chlamydial inclusion bodies, termed 
inclusion membrane (Inc) proteins.  Inc proteins are secreted to be part of the inclu-
sion membrane by the type III secretion (TTS) apparatus (Subtil et al., 2000).  Over 
40 candidate sequences for Inc have been hitherto identified in the genomes of C.
trachomatis and C. pneumoniae comprising about 3 % and 6 % of the whole ge-
nome, respectively (Bannantine et al., 2000).  The first Inc proteins, IncA, IncB and 
IncC were found in the C. psittaci inclusion membrane (Bannantine et al., 1998; 
Rockey et al., 1995).  Thereafter four additional Incs, IncD-G were discovered in C. 
trachomatis (Scidmore-Carlson et al., 1999).  So far, over 40 Inc proteins in C. tra-
chomatis and over 60 Incs in C. pneumoniae have been identified (Bannantine et al.,
2000).   The function of the Incs is not clear, but they may be involved in contact 
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with the cytosol of the host cell, e.g. in lipid trafficking from the Golgi region to the 
chlamydial inclusion (Bannantine et al., 2000).    
An additional set of 24 proteins that are TTS substrates but do not belong to the 
Inc family have been identified most recently in C. pneumoniae, C. trachomatis and 
C. caviae.  At least one of these newly characterized proteins translocates during 
proliferation from the chlamydial inclusion to host cell cytoplasm (Subtil et al.,
2005).  TTS proteins probably induce host cell responses to ensure favorable condi-
tions for chlamydial growth (Subtil et al., 2004). 
L i p o p o l y s a c c h a r i d e  ( L P S )  
All gram-negative bacteria carry a unique lipopolysaccharide (LPS, endotoxin) as a 
major constituent of the outer membrane.  LPS is a glycolipid compound comprised 
of three main structural domains: hydrophobic lipid A moiety, hydrophilic core 
oligosaccharide and O-polysaccharide moieties (Fig. 1).  O-polysaccharide, also 
termed O-antigen, is generally composed of 20 to 40 repeating sugar units, each of 
which comprises five sugar molecules.  O-polysaccharide is the outermost part of 
LPS.  The core oligosaccharide, which lies between the O-polysaccharide and lipid 
A moieties, is subdivided into an inner and outer core (Fig. 1).  Rough LPS types 
without O-polysaccharide are denoted Ra-Re forms according to their core oligosac-
charide composition (Fig. 1).   
The membrane anchor of LPS is called Lipid A, which constitutes an endotoxi-
cally active region of LPS (Seydel, 1998).  The structure of lipid A in various bacteria 
is relatively conserved, sharing 1, 4′-bisphosphorylated-β1, 6-linked N-acetyl-D-
glucosamine (NacGlc) disaccharide, which is acylated by four (R)-3-hydroxy fatty 
acids (of about 12-14 carbon atoms).   The fifth fatty acid is branched from the 3-
hydroxy fatty acid, which is acylated in glucosamine, whereas the location of the sixth 
fatty acid may differ (Rietschel et al., 1994; Zahringer et al., 1994).  Structural varia-
tions in lipid A are mainly found in the acylation pattern (Rietschel et al., 1996).
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Fig. 1.  LPS structure.  P, phosphate; KDO, 3-deoxy-D-manno-octulosonic acid; Hep, 
L-glycero-D-manno-heptose; Etn, ethanolamine; PEtn, phosphatidyl-ethanolamine, 
Glc, D-glucose; Gal, D-galactose, GlcNac, N-acetyl-D-glucosamine   
Chlamydial LPS (cLPS) is a well-characterized, surface-exposed antigen located 
on the outer membrane of Chlamydia.  The cLPS is truncated, lacking O-antigen, and 
is thus a phenotypically rough LPS (Nurminen et al., 1983).  However, an LPS 
smooth-rough phase variation in C. psittaci has been described (Lukacova et al.,
1994).  The cLPS consists of pentasaccharide containing lipid A moiety, which is 
covalently linked to a unique linear 3-deoxy-D-manno-octulosonic acid (KDO)-
trisaccharide (Fig. 2.) (Brade et al., 1987).  Quite recently, a new KDO-tetrasaccharide 
has been described for C. psittaci (Muller-Loennies et al., 2005).  Although the lipid A 
structure among gram-negative bacteria is rather similar, there are some essential 
structural variations in the cLPS lipid A moiety.  Acyl chains of cLPS lipid A are un-
usually long, composing over 20 carbon atoms.  Further, there is amide-linkage be-
tween the 3-hydroxy fatty acids (Brade et al., 1986; Nurminen et al., 1985).  To date, 
the structures of the LPS of C. trachomatis serotypes L2 (Rund et al., 1999) and E 
(Heine et al., 2003) as well as C. psittaci 6BC strain (Rund et al., 2000) and C. pneu-
moniae Kajaani 6 strain (Hussein et al., 2001) have been elucidated.
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Fig. 2.  Structure of core oligosaccharide in Chlamydiae (modified after Brade et al., 
1994). Monoclonal antibodies produced against epitopes 3 and 4 are Chlamydia-specific.
LPSs are considered a major antigen in gram-negative bacteria (Luderitz et al.,
1966a; Luderitz et al., 1966b).  LPSs can elicit a variety of pathophysiological re-
sponses, including fever, coagulant activity, and septic chock (Parrillo, 1993; Riet-
schel et al., 1992; Ulevitch et al., 1995).  LPSs may also activate an acute inflamma-
tory response by inducing the production of various inflammatory cytokines, such as 
tumor necrosis factor (TNF) α and interleukin (IL) 1β (Morrison et al., 1987; Raetz, 
1990; Rietschel et al., 1992).   
Yet, cLPS is less effective than e.g. enterobacterial LPS in eliciting inflamma-
tory a cytokine response in serum (Ingalls et al., 1995; Netea et al., 2002).  Nonethe-
less, cLPS is capable of inducing macrophage foam cell formation in the presence of 
exogenous LDL (Kalayoglu et al., 1998a).  The diminished biological activity of 
cLPS may be due to structural divergences, i.e. i) an unusual acylation pattern (five 
3
1
2
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acyl groups instead of six) ii) long fatty acid chains and iii) fewer hydroxy fatty 
acids attached to the glucosamine disaccharide (Qureshi et al., 1997).  Indeed, the 
LPS of C. trachomatis L2 displays up to 100 to 1000-fold less potency than the LPS 
of E. coli O55:B5 to induce TNFα secretion (Prebeck et al., 2003).  In serum-free 
conditions, however, cLPS is a more potent inducer of TNFα production than en-
terobacterial (E. coli O158:B8) LPS.  Since interactions with LPS-carrier proteins, 
e.g. LPS binding protein (LBP), are mediated by the lipid A part of LPS, it has been 
suggested that i) divergence in cytokine production is mainly due to structural dif-
fererences in the lipid A (Kalayoglu et al., 2000) and ii) LPS in serum-free condi-
tions interacts more efficiently with an LPS receptor on a monocyte surface and is 
transferred into the cell by the unknown mechanism.  Although in vitro studies sug-
gest the role of cLPS in atherogenesis, further studies are needed to confirm the 
biological mechanism of cLPS in this process. 
2.1.4   Developmental cycle 
Chlamydiae as obligate intracellular parasites of eukaryotic cells have a unique de-
velopmental cycle with two distinct morphological forms: extracellular, infective, 
metabolically inactive elementary body (EB) and intracellular, metabolically active 
multiplying reticulate body (RB).  Elementary bodies (EBs) are small, approxi-
mately 0.3 μm in diameter and have an electron-dense nucleoid.  RBs are substan-
tially larger, from 1 to 1.5 μm in diameter having an equally dispersed, reticulate 
cytoplasm (Friis, 1972).  Chlamydiae have traditionally been considered energy 
parasites; as incapable of producing the energy needed for replication, they are de-
pendent on adenosine triphosphate (ATP) derived from the host cell (Hatch et al.,
1982).  Surprisingly, ATPase genes have been found in chlamydial genome 
(Stephens et al., 1998), indicating ATP-producing capacity, which may be important 
in the early and late stages of the developmental cycle, when host cell ATP is not 
available (Hatch et al., 1982). 
 The first description of the chlamydial growth cycle was based on electron mi-
croscopic studies of C. trachomatis and C. psittaci in cell culture (Higashi, 1965).  
Details in the cycle diverge between the chlamydial strains and host cell involved 
(Higashi, 1965; Storz et al., 1977; Vanrompay et al., 1996).  The cycle is initiated 
by the endocytosis of an EB by a target host cell (Fig.3, A).  After inhibition of 
phagolysosomal fusion (B), the EBs differentiate to the RBs (C).  RBs replicate by 
binary fission inside the inclusion vesicles derived from the host cell lipids (D).  
Persistent aberrant chlamydial forms may develop at this phase under stress condi-
tions (e.g. interferon (IFN) γ exposure, penicillin, iron deprivation).  Abnormal RBs 
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no not divide nor mature into EBs.  Without stress, RBs differentiate back to EBs 
(E), the host cell is lysed, and EB forms are released to initiate a new round (F). 
Fig. 3.  Developmental life cycle in Chlamydia (modified after Rottenberg et al., 2002).   
2.1.5   Pathogenesis
C. pneumoniae survives and multiplies within the cell types found in a vascular 
atherosclerotic lesion including endothelial cells, smooth muscle cells, monocytes, 
macrophage-foam cells as well as T-lymphocytes (Airenne et al., 1999; Gaydos et 
al., 1996; Godzik et al., 1995; Haranaga et al., 2001; Kaukoranta-Tolvanen et al.,
1994).  The organism induces the production of several proinflammatory cytokines 
and inflammatory mediators, such as monocyte chemoattractant protein (Grube et 
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al.) 1, IL-8, TNFα and IL-1β (Jahn et al., 2000; Kaukoranta-Tolvanen et al., 1996; 
Krull et al., 2004; Molestina et al., 2000).  In vitro, the adherence and attachment of 
monocytes to aortic endothelial cells is accelerated by C. pneumoniae (Kalayoglu et 
al., 2001).  In addition, C. pneumoniae-infected monocyte-derived macrophages 
accumulate cholesterol esters and form cholesterol-loaded foam cells in the presence 
of LDL (Kalayoglu et al., 1998b). 
Monocytes have been suggested to serve as transport vehicles in the dissemination 
of C. pneumoniae to extrapulmonary organs.  Animal studies have clearly demon-
strated that C. pneumoniae can spread from the lungs to other sites (Campbell et al.,
1998) including aortic tissue (Fong et al., 1997; Hu et al., 1999; Moazed et al., 1997).  
The migration of C. pneumoniae-infected alveolar macrophages from the lungs into 
the bloodstream via the lymphatic route has been postulated to be involved in mice 
(Moazed et al., 1998) and rabbits (Gieffers et al., 2004).  Supporting this, several hu-
man studies have demonstrated circulatory C. pneumoniae DNA in peripheral blood 
mononuclear cells (PBMC) in patients with cardiac disease more frequently than in 
healthy controls (Boman et al., 1998; Freidank et al., 2002; Kaul et al., 2000; Maraha
et al., 2001; Sessa et al., 2001; Smieja et al., 2001; Wong et al., 1999). 
2.2 Diagnosis of acute C. pneumoniae infection 
2.2.1 Culture
Having earlier been considered a golden standard in the diagnosis of C. trachomatis,
chlamydial culture has not displayed such a strong position in the case of C. pneu-
moniae (Saikku, 1994).  C. pneumoniae culture is highly specific and most success-
ful in HL (Cles et al., 1990) and Hep-2 (Roblin et al., 1992) cell lines, reaching 50 
% sensitivity in the samples taken from antibody-positive subjects in acute infec-
tions (Ekman et al., 1993b; Grayston et al., 1993).  Lowered culture sensitivity in 
the case of C. pneumoniae may be due to the relatively low amount of EBs present 
in swab specimen or the poor ability of EBs to form inclusion (Saikku, 1994). 
2.2.2 Antigen detection 
Commercially available enzymeimmunoassay (EIA) kits for the detection of C. 
trachomatis LPS are basically applicable to the diagnosis of C. pneumoniae, too.  
However, based on the detection of a chlamydial group antigen from respiratory 
tract sample, these methods do not provide species-specificity.  C. pneumoniae, C. 
psittaci and occasionally even C. trachomatis can be present in the respiratory sam-
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ples.  Further, sensitivity is questioned by the small quantity of LPS proposed to be 
present in the samples (Saikku, 1994).   
Another method for antigen detection is direct staining with a fluorescently la-
beled antibody (FA).  Unlike C. trachomatis, C. pneumoniae EBs are more fragile 
and unstable under the harsh conditions that EBs undergo during fixation (Wang et 
al., 1991).  It is also difficult to obtain a representative sample from the respiratory 
tract.  Overall, staining with FA yields low sensitivity (20-60 %) and a skilled reader 
is required to gain specificity (Saikku, 1994).   
2.2.3 Serology
The earliest immune response in acute chlamydial infections is the development of 
IgM antibodies against cLPS (Ekman et al., 1993b).  In primary infections, IgM and 
IgG antibodies, measured by microimmunofluorescence (MIF), develop generally 
about 3 and 6-8 weeks after the first symptoms, respectively (Kuo et al., 1995a).  The 
diagnostic criteria for primary C. pneumoniae require 4-fold rise in the IgG titer 
(paired sera) and/or single titer of ≥16 for IgM (Dowell et al., 2001).  A weak IgM 
response can sometimes be observed in reinfections, when IgG and IgA antibodies 
appear fast, 1 to 2 weeks after the onset of illness (Grayston et al., 1990).  Because 
antibodies appear relatively late, serology has limitations in cases in which only acute 
phase serum is available.  Further, the antibody response may be missed if the conva-
lescent serum has been taken too early, i.e. less than 3 weeks after the onset of illness. 
Complement fixation (CF) was the first method applied to chlamydial serology.  
Genus-specific glycolipid (cLPS) is used as a CF-antigen and thus, the method does 
not permit discrimination between chlamydial species. In addition, the lack of an 
IgM antibody response against LPS reduces the sensitivity of CF in the elderly, who 
usually have reinfections (Grayston et al., 1990).   
MIF is considered the golden standard in chlamydial diagnosis.  It was first ap-
plied to the diagnosis of C. trachomatis infections (Wang et al., 1970).  According 
to the current recommendations for C. pneumoniae serology, MIF is considered the 
only satisfactory serological test (Dowell et al., 2001).  Methodologically, antibodies 
present in a serum sample first attach themselves to the EB antigen bound on a glass 
slide, and are then visualized via the binding of a secondary, FITC-labeled antibody.  
The method is highly specific and suitable for the measurement of IgA, IgG and 
IgM antibodies.  The restrictive point is that the reliable reading of an MIF test re-
sults requires an experienced microscopist.  Most of the MIF assays are in-house 
methods, but commercial assays are available, too.  However, there is no standard-
ized MIF test and different assay conditions have been shown to account for dis-
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crepant results between laboratories (Peeling et al., 1998).  Moreover, differences 
between the MIF antigen used and the C. pneumoniae isolate to be studied may 
result in variations between the results (Kutlin et al., 1998).   
As with MIF, EIA is also able to distinguish between IgA, IgG and IgM anti-
body classes.  In EIA, antibodies are trapped by a C. pneumoniae antigen bound to 
the solid phase (microtiter plate).  The antigen-antibody reaction is detected by the 
enzyme-labeled secondary antibody followed by a substrate reaction.  In commercial 
EIA kits, specificity, cut-off values, as well as the criteria for positivity vary from kit 
to another and make between-laboratory comparisons difficult (Boman et al., 2002).      
2.3 Diagnosis of chronic C. pneumoniae infection in cardiovascular 
diseases
Since chronic C. pneumoniae infection has been associated with a number of various 
diseases, the need for a satisfactory diagnostic method has emerged.  Although viable 
C. pneumoniae has recently been successfully isolated from atherosclerotic lesions, 
insensitivity and difficulties in isolation prevent the use of culture in the diagnosis of 
chronic C. pneumoniae.  Furthermore, in chronic conditions, C. pneumoniae can be 
penetrated into deeper sites and a representative sample may be challenging to obtain 
for culture or antigen detection (Saikku, 1994).  At present, there are no specific and 
sensitive methods for the diagnosis of chronic C. pneumoniae infection.
2.3.1 Serology
Both MIF and EIA methods are used for antibody measurement in chronic C. pneu-
moniae infections.  The first publication on the serological association of C. pneu-
moniae with CHD was based on the measurement of C. pneumoniae IgG and IgA 
antibodies by MIF (Saikku et al., 1988).  Although the presence of continuously 
elevated C. pneumoniae antibodies poorly reflects the actual site or phase of infec-
tion, it still may indicate chronic infection.  The biological half-life for IgA is about 
one week and over three weeks for IgG.  However, circulatory IgG antibodies have 
been suggested to persist after an acute C. pneumoniae infection for years (Kuo et 
al., 1995b; Paldanius et al., 2005).  Moreover, the usefulness of serology is poor in 
assessing the role of C. pneumoniae in cardiovascular disease patients, since the age-
matched controls are also at the age when seroprevalence can reach up to 80 % 
(Kalayoglu et al., 2002).   
The presence of elevated serum C. pneumoniae IgA and IgG antibodies with 
concomitantly increased levels of highly sensitive C-reactive protein (hsCRP) has 
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been associated with coronary risk, acute coronary syndromes and asthma (Huittinen
et al., 2003; Miya et al., 2004; Sävykoski et al., 2004).  Moreover, the presence of 
persistently elevated C. pneumoniae IgA titer together with elevated hsCRP levels  
is a significant risk factor combination for coronary events (Huittinen et al., 2003). 
2.3.2  Immune complexes
During C. pneumoniae infection, immune complexes containing cLPS (Leinonen et 
al., 1990) or chlamydial proteins (Linnanmäki et al., 1993) can be present in circula-
tion.  Continuous production of chlamydial antigens, such as cLPS, during chronic 
infection may lead to the continuous presence of circulating immune complexes in 
serum.  Indeed, elevated levels of cLPS-IgM immune complexes have been demon-
strated in coronary heart disease patients as a sign of the presence of C. pneumoniae
in the blood stream (Leinonen et al., 1990; Saikku et al., 1992).   
2.3.3 Polymerase chain reaction (PCR) 
Although PCR enables the detection of even nonviable C. pneumoniae, the goal to 
use PCR as a reliable diagnostic method is still far from resolved.  Boman et al. were 
the first to detect the C. pneumoniae Omp1 gene by nested PCR in the PBMCs of 
cardiac patients (Boman et al., 1998).  However, troubles both in the specificity and 
sensitivity as well as in the validation of new assays exist.  In addition, PCR corre-
lates poorly with MIF serology.  Differences in DNA extraction methods and PCR 
protocols have been suggested to account for variations in results.  Indeed, samples 
from same patients have produced significantly different PCR results when investi-
gated in different laboratories (Apfalter et al., 2001; Ramirez, 1996).   
2.3.4 Other methods 
In addition to PCR, C. pneumoniae has been detected from vascular tissue by sev-
eral other methods, including immunocytochemistry (ICC) and electron microscopy 
(EM).  The agreement among these methods is, however, very poor, with a low 
percentage of samples detected positive with the two methods (Campbell et al.,
1995; Grayston et al., 1995; Kuo et al., 1993a; Kuo et al., 1995a; Kuo et al., 1993b; 
Ong et al., 1996).  C. pneumoniae has also been detected in human atherosclerotic 
plaques and aortic valves by in situ hybridization, which allows for  the localization 
and quantification of chlamydial DNA (Mosorin et al., 2000; Pierri et al., 2005).  
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2.4 C. pneumoniae mouse models for atherosclerosis 
Animal models are useful tools in assessing the causality of pathogens and their 
impact on various diseases, e.g. on cardiovascular diseases.  Both rabbits and mice 
are generally used in elucidating the course of C. pneumoniae infection and its role 
in the initiation and progression of atherosclerosis.    
2.4.1 C. pneumoniae infection
Intranasal inoculation with C. pneumoniae causes self-limited pneumonia in mice 
(Kaukoranta-Tolvanen et al., 1993; Yang et al., 1993).  IgG antibodies against C.
pneumoniae begin to rise 10 to 12 days after the infection and the highest titers can 
be observed 3-4 weeks post infection, whereas maximum IgM levels are seen in 2-3 
weeks (Kaukoranta-Tolvanen et al., 1993; Yang et al., 1993). 
The clearance rate seems to be dependent on the C. pneumoniae isolate, the dose 
administered as well as on the mouse strain used (Erkkilä et al., 2000; Kaukoranta-
Tolvanen et al., 1993; Yang et al., 1993).  When administred with low doses of C.
pneumoniae, inflammatory changes in the lung occur more slowly, but can be de-
tected even after several weeks post inoculation (Kaukoranta-Tolvanen et al., 1993).  
Viable C. pneumoniae can be isolated generally up to 4 weeks, but sometimes even 
up to 6 weeks after infection (Kaukoranta-Tolvanen et al., 1993; Penttilä et al.,
1998; Penttilä et al., 1999; Yang et al., 1993).  After multiple inoculations, histopa-
thological changes in the lung may appear for up to 4 months (Moazed et al., 1997).   
After recovery, latent C. pneumoniae may remain in the lungs.  Latent forms 
can be reactivated and isolated from lung tissue after immunosuppressive cortisone 
therapy (Laitinen et al., 1996; Malinverni et al., 1995).     
2.4.2 C. pneumoniae, serum  lipids and atherosclerosis  
Mice as well as other rodents, like rats, are very resistant to atherosclerosis.  Among 
normal mouse strains, the only atherosclerosis-prone inbred strain is C57BL/6.  In 
these mice, atherosclerotic lesions develop under a hyperlipidemic diet (Blessing et 
al., 2001) or even under a small cholesterol supplement in the diet (Erkkilä et al.,
2004).  However, the lesions differ in their pathology and location from human le-
sions.  To create conditions in which lesions resembling those in human atheroscle-
rosis develop, genetically modified animals and/or a hyperlipidemic diet are needed.  
For this purpose, animals with a deficiency in lipoprotein metabolism like the LDL 
receptor knockout (LDLR KO) mice (Ishibashi et al., 1993) and apoE knockout 
(apoE KO) mice (Plump et al., 1992) have been used.  
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Several studies with mice have revealed that intranasally inoculated C. pneumo-
niae can disseminate from the lungs to the aorta and other tissues and, further, that 
C. pneumoniae promotes and accelerates atherosclerosis in mice.  Various mouse 
strains differ in their susceptibility to C. pneumoniae infection and atherosclerosis 
(Paigen et al., 1990).  Despite the postulation that C. pneumoniae is not an inde-
pendent risk factor for atherosclerosis, but rather acts in concert with high serum 
lipids (Blessing et al., 2001; Blessing et al., 2002; Ezzahiri et al., 2002; Hu et al.,
1999; Liu et al., 2000; Moazed et al., 1999), there are some studies in normolipi-
demic mice emphasizing the role of C. pneumoniae in triggering inflammation in the 
aorta and the progression of atherosclerosis (Blessing et al., 2000; Erkkilä et al.,
2004).   Baseline cholesterol levels among different mouse strains vary strongly and 
are dependent on genetic background (Table 2.). 
               Table 2.  Serum total cholesterol levels among mouse strains.    
  Mouse strain Serum total cholesterol (mmol/l) 
Regular chow      High fat diet 
NIH/S 2.5-3.5 5-6 
C57Bl/6J 2.5-3.5 5-6 
         •LDLR KO 5-10 35-40 
        •ApoE KO 10-15 35-40 
ApoE3-Leiden 10-15 35-40 
 C 5 7 B L / 6 J  m o u s e  m o d e l  
The susceptibility of C57BL/6J mice to atherosclerosis has been shown to be due to 
the s-allele form in the Ath-1 gene in chromosome 1 (Paigen et al., 1987).  During a 
normal chow diet in C57BL/6J mice cholesterol levels, mainly in HDL, are about 
2.5-3.5 mmol/l and during a high fat diet can rise up to 3-fold with the majority of 
cholesterol being distributed in the LDL and VLDL fractions (Paigen et al., 1987).  
No lesion formation is detected under normal chow, whereas first stage lesions with 
macrophage-foam cells are formed in a subendothelial intimal space near the aortic 
valve during a high fat diet (Paigen et al., 1985).   
In C57BL/6J mice, persistent infection in the aorta can be established by multi-
ple C. pneumoniae inoculations (Campbell et al., 1998).  C. pneumoniae infection 
alone in normolipidemic C57BL/6J mice causes inflammatory changes and intimal 
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thickening in the aorta (Blessing et al., 2000), which are characterized as very early 
stages in the atherosclerotic process (Stary et al., 1995), although no lesions can be 
detected (Blessing et al., 2000).  Erkkilä et al. recently demonstrated after two C. 
pneumoniae reinfections that C57BL/6J mice on a 0.2 % cholesterol supplement diet 
develop larger early lesions in the aorta compared to uninfected control mice 
(Erkkilä et al., 2004).  Erkkilä et al. did not see any changes in serum total lipids, 
nor did Blessing et al., who reported that C. pneumoniae in combination with a hy-
perlipidemic diet enhances aortic lesion formation in C57BL/6J mice (Blessing et 
al., 2001).  This accelerating effect of C. pneumoniae on lesion formation in 
C57BL/6J mice has been demonstrated to be partly mediated via the induction of 
TNF-α production, since the effect of C. pneumoniae can be abolished in the p55, 
TNF-α receptor, KO mice (Campbell et al., 2005).  Another additional mechanism 
behind the atherogenic effect of C. pneumoniae may be the due to increased induc-
ible nitric oxide synthase (iNOS) activity (Chesebro et al., 2003).  iNOS is ex-
pressed in a variety of cell types as a response to inflammation and cytokines 
(Kleinert et al., 2003). 
Details in the study design and execution are critical in C. pneumoniae mouse 
models.  Differences in the experimental conditions, such as the C. pneumoniae dose 
and infection intervals may account for the negative results with C57BL/6J mice 
(Caligiuri et al., 2001). 
A p o E  K O  a n d  A p o E 3 - L e i d e n  m o u s e  m o d e l s  
ApoE is a glycoprotein essential for the clearance of VLDL and chylomicron rem-
nants (Meir et al., 2004).  As a consequence of apoE deficiency, serum total choles-
terol in homozygous apoE KO mice is elevated up to 10-15, primarily in the VLDL 
fraction.  Moreover, triglyceride levels are approximately 70 % higher than those in 
normal mice (Plump et al., 1992).  ApoE KO mice spontaneously develop athero-
sclerosis even under regular chow (Nakashima et al., 1994).  Lesion formation can 
be accelerated and exacerbated with a high fat diet, while VLDL cholesterol levels 
can be further elevated about 3-fold (Plump et al., 1992).  Lesions observed in the 
apoE KO mice resemble those detected in humans, i.e. mice develop advanced le-
sions with fibrous caps at vascular branch points (Reddick et al., 1994).   Primary C. 
pneumoniae infection in hyperlipidemic apoE KO mice causes an elevation in 
triglycerides, although no effect on lesion formation was observed (Aalto-Setälä et 
al., 2001).  Secondary C. pneumoniae infection, however, even in normolipidemic 
apo E KO mice, increases lesion size in the aorta and induces a significant increase 
in serum total triglyceride levels (Rothstein et al., 2001).  Several differences in the 
study design, such as C. pneumoniae strain and dose, infection intervals as well as 
the site of lesions to be analyzed may account for the conclusion of the minor role of 
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C. pneumoniae as a risk factor in the atherosclerosis in apoE KO mice (Aalto-Setälä
et al., 2001; Caligiuri et al., 2001).   
Another mouse model, transgenic ApoE3-Leiden mice on a C57BL1/6J back-
ground, was used when studying the effects of C. pneumoniae infection on lesion 
progression (Ezzahiri et al., 2002).  The ApoE3-Leiden mutation in the apoE gene is 
associated with the predominantly inherited form of familial type III hyperlipopro-
teinemia (Havekes et al., 1986).  ApoE3-Leiden transgenic mice display primarily in 
elevated levels of VLDL and LDL.  In ApoE3-Leiden mice, C. pneumoniae pro-
motes the development of more complex lesions, which shift towards more severe 
and complex lesions with fibroatheroma in nine months (Ezzahiri et al., 2002).   
L D L R  K O  m o u s e  m o d e l  
LDLR KO mice were originally created for a model of familial hypercholesterolemia 
(FH).  The serum lipid abnormalities in LDLR KO mice are not so serious compared 
to those observed in apoE KO mice.  The majority of the serum total cholesterol is 
found in the LDL fraction.  During chow, serum total cholesterol is about 5-10, and 
mice do not develop atherosclerosis unless fed with a Western type of high fat diet, in 
which cholesterol levels rise up to 6-fold and in the intermediate fibro-proliferative 
stage, large lesions are formed (Ishibashi et al., 1994).  Serum lipids and lipoproteins 
remain unchanged during multiple C. pneumoniae infections (Hu et al., 1999; Liu et 
al., 2000).  However, C. pneumoniae infection increases lesion size and intima thick-
ening and generates more severe lesions with necrotic cores and fibrous caps in LDLR 
KO mice in nine months (Hu et al., 1999).  The atherogenic effect of Chlamydiae has 
been demonstrated to be specific for C. pneumoniae, and dependent on simultaneous 
cholesterol supplement in the diet (Hu et al., 1999). 
2.5 LPS metabolism 
In gram-negative bacterial infections, LPS is one of the most potent inducers of an 
inflammatory reaction by activating a wide variety of cell types.  A small amount of 
LPS is beneficial to mount an immune defence, whilst exposure to large amounts of 
LPS may trigger massive destructive cellular responses.  Therefore, a host’s mecha-
nisms for endotoxin inactivation are essential. 
The detoxification process includes the incorporation of the lipid A part into the 
phospholipid-rich surface of lipoproteins (Read et al., 1993).  The major lipoprotein 
classes, HDL, LDL, VLDL and chylomicrons (CMs) have been demonstrated to be 
able to sequester and neutralize LPS (Harris et al., 1990; Harris et al., 1993; Netea et 
al., 1998; Ulevitch et al., 1979; Van Lenten et al., 1986; Victorov et al., 1989).  
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During clearance, the endotoxin anchored to lipoproteins is shunted to hepatocytes 
via receptor-mediated uptake and further excreted in bile (Read et al., 1993).      
The lipopolysaccharide binding protein (LBP) is a 60 kDa acute phase protein 
(Schumann et al., 1996; Schumann et al., 1999) which is elevated during bacterial 
infections.  LBP belongs to the LPS binding/lipid transfer protein family together 
with phospholipid transfer protein (PLTP), cholesterol ester transfer protein (CETP) 
and neutrophil bacteridical permeability increasing protein (BPI).  Although princi-
pally produced by the liver, LBP is also expressed in lungs, kidneys and heart 
(Schumann et al., 1996; Schumann et al., 1999).  In the liver, LBP expression can be 
induced by IL-1 and IL-6 (Grube et al., 1994; Ramadori et al., 1990; Wan et al.,
1995).  In normal human serum, the LBP concentration ranges from 5-10 μg/ml 
increasing up to 10-30 fold during the acute phase response (APR) (Blairon et al.,
2003; Froon et al., 1995; Opal et al., 1999).   
LBP has a pivotal role in LPS metabolism.  In circulation, LBP is able to facili-
tate the neutralization of LPS by transferring LPS from the bacterial outer membrane 
or LPS aggregates to HDL (Hailman et al., 1996a; Van Lenten et al., 1986; Vesy et 
al., 2000).  HDL-associated LPS can be subsequently delivered to LDL or VLDL 
(Levels et al., 2001), a process accelerated in the presence of LBP and PLTP (Levels
et al., 2005).  PLTP and LBP are boomerang-shaped proteins containing two lipid 
binding pockets apparently important in the transfer of LPS (Huuskonen et al.,
1999).  LBP was first found in close association with free apoA-I and apoA-I-
containing HDL particles (Massamiri et al., 1997; Wurfel et al., 1994).  Contradic-
tory data has also been reported suggesting that circulatory LBP is associated mainly 
with apoB-containing lipoproteins (LDL and VLDL) in vivo both in healthy indi-
viduals and in patients with an inflammatory condition (Vreugdenhil et al., 2001).   
Another pathway in LPS metabolism is capable of triggering an inflammatory re-
sponse.  LBP may result in target cell activation and lead to the release of inflamma-
tory mediators and cytokines by transferring LPS to either membrane bound (mCD14) 
or soluble CD14 (sCD14) protein.  The mCD14 is a 55 kDa, LPS responsive pattern-
recognition receptor protein on the surface of monocytes and neutrophils (Viriyakosol
et al., 1996).  Endothelial and human coronary artery smooth muscle cells 
(HCASMCs), previously considered to be CD14 negative cells, have recently been 
shown to express functional mCD14 (Jersmann et al., 2001; Stoll et al., 2004).  Serum 
sCD14 is a prerequisite for the activation of CD14 negative cells by LPS but has also 
been shown to participate in the activation of CD14 expressing cells (Frey et al., 1992; 
Hailman et al., 1994; Hailman et al., 1996b; Kitchens et al., 1998).
The mCD14 has neither a transmembrane nor cytoplasmic domain and thus, ac-
cessory proteins are required to mediate intracellular signal transduction.  One of 
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these accessory proteins is a Toll-like receptor 4 (TLR-4), a member of the Toll-like 
receptor family (Means et al., 2000), which has been demonstrated to be connected 
to the endotoxin-CD14 complex (Chow et al., 1999).  Another substantial LPS rec-
ognition protein of the receptor complex is MD-2, which has been shown to bind 
both LPS and CD14 (Gioannini et al., 2004; Nagai et al., 2002; Shimazu et al.,
1999; Viriyakosol et al., 2001).  Eventually, after multiple interactions with intracel-
lular proteins, cellular activation by LPS leads to the activation of the nuclear factor 
κB (NF-κB) and its translocation to the nucleus followed by the expression of in-
flammatory cytokines (Fitzgerald et al., 2004).  
The distribution of LPS in serum is strongly dependent on the concentrations of 
LPS-binding/associated proteins.  For example, LBP-mediated LPS transfer to lipo-
proteins has been shown to be enhanced in the presence of sCD14 (Wurfel et al.,
1995).  Also, the LBP/sCD14 ratio may determine the targeting of LPS transfer in 
circulation.  During APR, sCD14 levels increase maximally by 2-fold whereas LBP 
levels are elevated by 10-30-fold (Froon et al., 1995).  An increased LBP/sCD14 ratio 
is appropriate for enhanced LPS clearance rather than cellular activation (Landmann et 
al., 1995).  Accordingly, the lower LBP/sCD14 observed in chronic infections may 
implicate enhanced capacity of LPS to activate cells (Tapping et al., 2000). 
2.6 Infection, inflammation and lipoprotein metabolism 
The body’s response to infection and inflammation is known as the acute phase 
response (APR), which is responsible for the release of several cytokines.  Cytokines 
mediate multiple changes in lipid metabolism.  The direction of change in cytokine 
pools and thereby in lipid levels during human infections varies between pathogens.  
Further, the direction and extent of inflammatory alterations in the distribution of 
lipids are species-specific (Feingold et al., 1993a; Grunfeld et al., 1992; Sammal-
korpi et al., 1988).    
2.6.1 Overview on lipoprotein metabolism  
Lipoprotein metabolism can be divided into two major pathways: the intestine-derived 
exogenous and the liver-derived endogenous pathway.  Dietary lipids, cholesterol and 
triglycerides, are delivered by the exogenous pathway and absorbed via intestinal en-
terocytes where they are assembled into chylomicrons (CMs).  Once entered into gen-
eral circulation, lipoprotein lipase (LPL) hydrolyses the triglyceride-rich core of CM-
producing chylomicron remnants.  Chylomicron remnants are taken up by the liver 
preferentially via the LDL-receptor related protein (LRP).  In addition, LDL-receptor 
(LDLr) can also be involved in this process (Packard et al., 1999).
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In the endogenous pathway, lipids (triglycerides, cholesterol, phospholipids) in 
the liver are assembled and excreted in the form of VLDL.  The main apolipoprotein 
in VLDL is apolipoprotein B 100 (apoB-100).  LPL hydrolyzes the triglycerides in 
the VLDL particle, resulting in the formation of phospholipid-rich surface compo-
nents and VLDL remnants.  Via LPL action, VLDL remnants can be further trans-
formed to intermediate density lipoprotein (IDL).  Phospholipid surface remnants 
are transferred to HDL by phospholipid transfer protein (PLTP) (Jiang et al., 1999), 
a process important in the maintenance of serum HDL levels.  IDL particles are 
further hydrolyzed by LPL and hepatic lipase (HL), resulting in the formation of 
LDL (Goldberg, 1996; Nilsson-Ehle et al., 1980).  Cholesterol-rich LDL particles 
are cleared from circulation mainly via LDL receptors (Brown et al., 1986).  Antia-
therogenic HDL is biosynthesized with apoA-I as the major apolipoprotein compo-
nent in the liver, but some amount of the apoA-I also originates from the intestine 
(Barter et al., 2003; Eisenberg, 1984; Linsel-Nitschke et al., 2005). 
2.6.2 Changes in VLDL metabolism during inflammation 
One of the main characteristics and consistent changes in lipid levels during APR is 
the elevation of serum triglycerides (Alvarez et al., 1986; Cox et al., 1975; Fiser et 
al., 1972; Friedland et al., 1982; Vergani et al., 1978).  In experimental animals, low 
doses of LPS, used to mimic mild infection, causes the production of fatty acids by 
increased adipose tissue lipolysis and hepatic de novo fatty acid synthesis as well as 
the decreased hepatic fatty acid β-oxidation.  Fatty acids are then esterified into 
triglycerides and assembled into VLDL particles in the liver (Memon et al., 1992; 
Memon et al., 1993).  In contrast, administration with higher LPS doses reduces the 
activity of LPL and the expression of apoE, both of which are essential for proper 
VLDL clearance (Feingold et al., 1992; Hardardottir et al., 1997; Tripp et al., 1993).  
In humans, serum total and VLDL triglycerides are elevated during inflammatory 
conditions (Alvarez et al., 1986; Grunfeld et al., 1991; Khovidhunkit et al., 2004; 
Sammalkorpi et al., 1988). 
2.6.3  Changes in LDL and HDL metabolism during inflammation 
Another inflammatory change in human lipids during infection is the decrease in 
serum total cholesterol (Sammalkorpi et al., 1988; van Leeuwen et al., 2003).  The 
mechanisms behind the decrease in cholesterol are not entirely clear.  In animals, 
cholesterol changes are species-specific and dependent on infective agent as well as 
the severity and stage of illness (Alvarez et al., 1986; Feingold et al., 1992; Fiser et 
al., 1972; Fiser et al., 1971; Gallin et al., 1970; Ziegler et al., 1992).  Although LPS 
and some cytokines, such as TNFα and IL-1, activate in rodents 3-hydroxy-3-
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methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme in cho-
lesterol biosynthesis pathway, only a moderate increase is observed in hepatic or 
serum cholesterol levels (Feingold et al., 1993a; Feingold et al., 1995; Hardardottir
et al., 1994).  The explanation for the small increase in cholesterol levels by LPS 
and cytokines is the decreased activity of squalene synthase, another enzyme down-
stream in the cholesterol synthesis pathway (Memon et al., 1997). 
On the basis of human studies, total cholesterol reduction seems to be related to 
the severity of infection rather than to the causative agent (Sammalkorpi et al., 1988; 
van Leeuwen et al., 2003), although a correlation to either ones is not always dem-
onstrated (Alvarez et al., 1986).  The decline in cholesterol can be ascribed to the 
reduction of esterified cholesterol mainly in LDL and but also in the HDL fraction 
(Gordon et al., 1996; Kitchens et al., 2003; Sammalkorpi et al., 1988; van Leeuwen
et al., 2003).  In vitro studies using human HepG2 cells indicate that IL-1 and IL-6 
decrease apolipoprotein and cholesterol accumulation in a medium by affecting 
cholesterol synthesis and secretion or both (Ettinger et al., 1994).  
Infection and inflammation do not merely affect HDL lipid levels but also 
change the levels of several HDL-associated proteins (Fig. 4).  Concentrations of 
apoA-I and paraoxonase (PON) are reduced (Clifton et al., 1985; Van Lenten et al.,
2001), whereas the level of HDL-associated acute phase protein, serum amyloid A 
(SAA), can be elevated up to 1000-fold (Cabana et al., 1989; Kisilevsky et al., 2002; 
Van Lenten et al., 1995).  SAA displaces apoA-I (Cabana et al., 1999; Coetzee et 
al., 1986) and PON (Cabana et al., 2003) from the surface of HDL particles.  PON 
has an important antioxidant function by metabolizing lipid peroxides and protecting 
against their accumulation in LDL (Aviram et al., 2000; Draganov et al., 2000) and, 
consequently, decreased PON activity during the acute phase may contribute to the 
decreased antioxidant potential of HDL (Van Lenten et al., 1995).  Another enzyme 
protecting LDL from oxidation is platelet-activating factor-acetylhydrolase (PAF-
AH), of which about 30 % is bound in HDL in humans (Stafforini et al., 1997).  The 
effects of APR on PAF-AH are controversial, varying among animals (Howard et 
al., 1997; Van Lenten et al., 1995).  In humans, PAF-AH activity increases signifi-
cantly in several diseases (Claus et al., 2005; Endo et al., 1994; Khovidhunkit et al., 
1999).  The anti-inflammatory phenotype of HDL is changed to pro-inflammatory 
type due to these protein changes.        
28
Fig. 4.  Proinflammatory properties in HDL generated during inflammation. SAA, serum 
amyloid A; PON, paraoxonase; PAF-AH, platelet-activating factor-acetylhydrolase. 
During the acute phase, alterations in some key regulatory enzymes involved in 
HDL metabolism are observed, including decreased lecithin-cholesterol acyltrans-
ferase (LCAT), cholesterol ester transfer protein (CETP) and HL activities (Feingold
et al., 1999; Hardardottir et al., 1996; Khovidhunkit et al., 2001; Ly et al., 1995; 
Sammalkorpi et al., 1988).  In contrast, activity of the other serum lipid transfer 
protein, PLTP is increased (Barlage et al., 2001). 
The main regulatory pathways in HDL metabolism during inflammation are de-
scribed in Figure 5.  The primary function of LCAT is to convert free cholesterol 
into cholesterol esters in HDL particles (Barter et al., 1999).  Esterified cholesterol 
in HDL is exchanged by the function of CETP for VLDL triglycerides (Tall, 1993).  
Subsequently, HDL becomes depleted in cholesterol esters and triglyceride-enriched 
and thus, displays good substrate properties for HL (Barrans et al., 1994).  HL me-
tabolizes these large triglyceride-enriched HDL into small size HDL particles with a 
concomitant formation of preβ-HDL.  According to current knowledge, small HDL 
particles can be metabolized via the kidney function (Kozyraki et al., 1999).  Preβ-
HDL is the initial acceptor for peripheral cell cholesterol in a reverse cholesterol 
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transport (RCT) pathway (Fielding et al., 1995).  PLTP transfers phopholipid be-
tween HDL subclasses and VLDL and LDL and promotes a fusion of small size 
HDL particles into large size HDL with a subsequent release of preβ-HDL 
(Jauhiainen et al., 1993; Nishida et al., 1993; Tollefson et al., 1988).
Fig. 5.  Inflammation and regulation of HDL subclasses.  LCAT, lecithin-cholesterol acyl-
transferase; PLTP, phospholipid transfer protein; HL, hepatic lipase, CETP, cholesterol 
ester transfer protein; ABCA1, ATP-binding cassette transporter A1. 
Although the changes in lipid metabolism during infection are generally tran-
sient, a prolonged inflammatory state, however, can be detrimental to the host.  It 
has been proposed that in the acute phase, HDL loses its unique properties as anti-
inflammatory and antiatherogenic lipoprotein (Van Lenten et al., 2001).  First, the 
function of HDL in the reverse cholesterol transport process from the peripheral 
cells may be impaired.  In addition, recent data also demonstrates that LPS directly 
downregulates the gene expression of the two HDL receptors, the ATP-binding 
cassette transporter A1 (ABCA1) and scavenger receptor B1 (SR-B1) involved in 
cholesterol efflux (Baranova et al., 2002).  Secondly, the ability of HDL to protect 
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LDL against oxidation may also be reduced (Khovidhunkit et al., 2000).  Thirdly, 
although LDL levels generally decrease during infection, the formation of highly 
atherogenic small dense LDL (sLDL) has been detected (Feingold et al., 1993b).  
All these changes in lipoproteins are characterized as pro-atherogenic.  
Several lines of evidence demonstrate that C. pneumoniae may contribute to 
atherosclerosis via lipoprotein metabolism.  For instance, infection by C. pneumo-
niae is associated with decreased HDL cholesterol and increased triglyceride con-
centration (Laurila et al., 1997; Murray et al., 1999).  Further, C. pneumoniae have 
been shown to promote LDL oxidation and macrophage foam cell formation in vitro
(Dittrich et al., 2004; Kalayoglu et al., 1998b; Kalayoglu et al., 1999).  Finally, the 
direct demonstration of C. pneumoniae in atherosclerotic plaques (Shor et al., 1992) 
demonstrates its ability to disseminate from the respiratory tract to circulation and 
particularly, to the site of lesion formation.       
                      
2.7  Statins as cardiovascular drugs 
Statins are HMG-CoA reductase inhibitors.  Statins prevent hepatic cholesterol biosyn-
thesis by blocking the HMG-CoA reductase, an enzyme that catalyzes the rate-limiting 
step in cholesterol biosynthesis (Endo et al., 1977).  Although statins are widely used in 
the treatment of hypercholesterolemia, several lines of evidence indicate that statins do 
not only decrease endogenous cholesterol synthesis but they possess anti-inflammatory 
effects.  Overall, statin treatment has reduced morbidity and mortality in CHD patients 
(Pedersen, 1994; Pedersen et al., 1998; Shepherd et al., 1995). 
2.7.1   Lipid lowering effect 
In humans, statins cause a reduction in serum LDL cholesterol and an elevation in 
HDL cholesterol.  Various statins differ in their ability to lower LDL cholesterol 
levels in serum (Vaughan et al., 2004).  A reduction in LDL levels is caused by both 
enhanced LDL uptake and decreased LDL secretion.  Decreased liver cholesterol 
synthesis leads to the activation of sterol regulatory element-binding proteins 
(SREBP) and enhances the expression of their target genes, including LDL receptors 
(Brown et al., 1997).  Subsequently, the clearance of LDL and LDL precursors from 
the circulation is increased.  Statins have also been suggested to inhibit the apoB-
100 synthesis in the liver, leading to a reduction in the synthesis and secretion of 
triglyceride-rich lipoproteins, VLDL (Vega et al., 2003).  During statin medication, 
VLDL levels are further decreased due to decreased serum triglycerides (Bakker-
Arkema et al., 1996; Stein et al., 1998).       
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The mechanism by which statins increase HDL is not entirely known.  In fact, 
the increase in HDL cholesterol achieved by statin use is relatively low (5-10 %).  
Despite the ability of statins to induce apoA-I production, a large variation in apoA-I 
induction capacity has been observed (Maejima et al., 2004). 
2.7.2   Anti-inflammatory effect 
Cholesterol lowering is not the only beneficial effect yielded by statins.  Statins have 
been shown to decrease serum CRP levels, improve endothelial function, stabilize 
atherosclerotic plaques and possess anti-inflammatory effects (Albert et al., 2001; 
Jialal et al., 2001; Kinlay et al., 2003; Ridker, 2003; Ridker et al., 2001).   
A n t i - c h l a m y d i a l  e f f e c t  
The ameliorating effect of simvastatin during C. pneumoniae infection has been 
reported (Erkkilä et al., 2005).  The mechanism by which the anti-inflammatory 
effect of statins is mediated is not completely understood.  C. pneumoniae-infected 
macrophages and endothelial cells release a decreased amount of MCP-1 and IL-8 
when coincubated with cerivastatin.  Supporting this finding, cerivastatin decreases 
the activation of NF-κB, a protein which regulates the expression of several cyto-
kines and chemokines, including IL-8 and MCP-1.  The inactivation of NF-κB is 
mediated via the Rho signaling pathway, and inhibition of this pathway leads to 
decreased NF-κB activity in C. pneumoniae infected cells (Dechend et al., 2003).   
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3 AIMS OF THE STUDY 
Different animal models have been utilized to elucidate the role of C. pneumoniae in 
the development of atherosclerosis.  Although C. pneumoniae is linked to pro-
atherogenic serum lipid profiles, little is known about its effects in mice.  Moreover, 
the beneficial effects of statins on lipid profile and inflammation have been reported, 
but whether the statin therapy modulates C. pneumoniae infection in a mouse model 
is not known.  Therefore, the aims in the present mouse studies were: 
I: To investigate the effect of acute C. pneumoniae infection on serum lipids, lipo-
protein distribution and lipolytic enzymes in an NIH/S mouse model. 
II: To investigate the effect of pravastatin treatment on C. pneumoniae infection, infec-
tion-induced inflammatory response and serum total lipids in an NIH/S mouse model. 
Atherosclerosis is considered to be an inflammatory disease and a link between se-
rum highly sensitive CRP (hsCRP) and cardiac events has been demonstrated.  Al-
though several studies have suggested an association between C. pneumoniae infec-
tion and atherosclerosis, the lack of reliable direct methods for the diagnosis of 
chronic C. pneumoniae infection has hampered these studies and contradictory find-
ings have been reported.  Therefore, the specific aims of the human studies were: 
III: To develop a specific enzyme immunoassay (EIA) method for cLPS quantifica-
tion in serum.  
IV: To investigate the correlation between serum hsCRP and cLPS levels in patients 
with acute coronary syndrome (ACS) during a one-year follow-up period.  
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4 MATERIALS AND METHODS 
4.1 Materials
4.1.1 Experimental animals (I, II) 
Female NIH/S (National Institute of Health/S) mice were purchased from the Na-
tional Public Health Institute (Animal Care Center, Kuopio, Finland).  The mice 
were fed either an autoclaved regular diet (Altromin, Chr. Petersen A/S, Ringsted, 
Denmark) or an high-fat diet (21 % total fat, 0.2 % cholesterol and 19.5 % casein, 
Harlan Teklad, NM Horst, the Netherlands). 
4.1.2 Human subjects (III, IV) 
Acute coronary syndrome (ACS) patients were recruited between September 1998 
and December 2000 from nine Finnish hospitals.  The ethics committees of the par-
ticipating hospitals approved the study, and all patients gave written informed con-
sent.  Serum samples were collected from patients with ACS within 48 hours after 
admittance to the hospital.  Patients with the following criteria were included: sub-
jects who entered hospital with prolonged chest pain with documented changes in 
ST-T waves indicating either unstable angina or a non-Q-wave myocardial infarc-
tion.  During the follow-up time, samples were taken one week, three months and 
one year after the ACS event.  Age- and sex-matched healthy blood donors obtained 
from Finnish Red Cross served as controls in the study III.   
4.2 Methods
4.2.1 Inoculation of NIH/S mice (I, II) 
Intranasal inoculation of C. pneumoniae was given during methoxyflurane anesthe-
sia.  The challenge dose was 5.3 *105 inclusion forming units (IFU)/mice in a sac-
charose-phosphate-glutamate (SPG) buffer.  The control mice were inoculated simi-
larly with (SPG).  Serum samples were taken at -3, 0, 3, 6, 9, 14, and 20 days postin-
fection.  Serum and tissue samples from 6 mice/group were collected after a fasting 
period of four hours three days prior to inoculation (day -3) at inoculation day (day 
0), and 3, 6, 9, 14 and 20 days post C. pneumoniae infection (p.i.).   
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4.2.2 Statin administration (II) 
Pravastatin treatment was given daily as an intraperitoneal injection in a 100 μl vol-
ume starting three days prior to infection (day -3) and continuing thereafter to the 
end of the follow-up period.  The pravastatin dosage was 0.5 mg/kg/day.  The inocu-
lation and sampling were carried out as described (see chapter 4.2.1).   
4.2.3 Monoclonal a-LPS antibodies 
Mouse monoclonal a-LPS antibodies produced against C. trachomatis LPS were 
purchased from Medix Biochemica (Espoo, Finland).  In EIA development, three 
monoclonal antibody clones 6701 (IgG1), 6703 (IgG2a) and 6709 (IgG2a) were tested. 
4.2.4 cLPS-enzyme immunoassay (III) 
Microtiter plates were coated with a mouse monoclonal antibody (0.5 μg/well) spe-
cific to chlamydial LPS for 16 h at +20 °C.  Blocking of non-specific binding sites 
was performed by phosphate-buffered saline (PBS) supplemented with 0.2 % defat-
ted milk (1 h at +37 °C).   
Serum samples were diluted 1/50 in 0.1 % octylglucoside-PBS, and LBP at 1 
μg/ml in 0.1 % Tween and added together to the plate (60 μl of each).  The mixture 
was incubated for 90 min at +37 °C.  During incubation, LBP solubilizes LPS from 
complexes in the serum by binding to the lipid A portion of LPS.  The sugar part of 
LPS then binds to the monoclonal a-LPS antibody coated on the plate.  Polyclonal 
rabbit anti-LBP antibody (100 μl of 1/500 dilution in Tween-PBS), added next, 
binds to LBP during a one-hour incubation at +37 °C.  Finally, detection is carried 
out by adding peroxidase-labeled goat anti-rabbit antibody (GAR-HRP, 1/10 000 
dilution in 0.1 % Tween-PBS supplemented with 10 % FBS) followed by incubation 
with an HRP-substrate for 1 h at +20 °C in the dark.  After stopping the reaction 
with 50 μl of 3 M H2SO4, absorbance is read at 490 nm. 
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4.2.5 Other methods
The other methods used in the original articles are summarized below. 
     ORIGINAL 
METHOD PUBLICATION
cholesterol concentration I - IV 
triglyceride concentration I- IV 
PLTP activity I
HL activity I
LCAT activity I
size-exclusion chromatography I, II 
LBP-ELISA I, II 
C. pneumoniae culture I, II 
MIF I - IV 
KDO-analysis III
phenol-water extraction III
SDS-PAGE III
hsCRP concentration IV
statistical analysis I - IV 
silver staining III
4.2.6 Statistics 
The Mann-Whitney U-test was used to inter-group comparisons (I, II, III).  Wil-
coxon’s signed ranks test was performed to compare the pooled serum values 
(LCAT-activity) between the groups within the study period (II).  A chi-squared test 
was used to compare the proportions of LPS-positive samples between the study 
groups.  The diagnostic applicability of cLPS for identifying ACS patients was 
evaluated by using the area under the receiver operating characteristic (ROC) curve.  
In Study IV, proportions were compared with a chi-square test or Fisher’s exact test, 
and quantitative data with a t-test or the Mann-Whitney test. The correlations were 
calculated with Spearman’s rank correlation test.  P-values of < 0.05 were consid-
ered statistically significant.      
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5 RESULTS AND DISCUSSION 
5.1 Effect of acute C. pneumoniae on lipoprotein metabolism in 
NIH/S mice (I) 
The C. pneumoniae NIH/S mouse model has been generally used to investigate the 
infection course and techniques (Erkkilä et al., 2002; Erkkilä et al., 2000; Kaukoranta-
Tolvanen et al., 1995).  Using chow-fed NIH/S mice, the aim was to study the effect 
of acute C. pneumoniae infection on serum lipids and lipolytic enzymes to clarify 
whether this mouse model can be utilized to draw conclusions in a human context.     
5.1.1 Infection and inflammation 
During C. pneumoniae infection, none of the mice showed any clinical symptoms of 
illness.  Successful infection was confirmed by antibody measurement and lung 
culture.  IgG antibodies started to increase 9 days p.i. and viable Chlamydia could be 
isolated by culture from infected mice on day 3 p.i. (I, Fig. 1).  All mice turned cul-
ture-negative towards the end of the follow-up.  LBP, a known acute phase protein, 
increased in both control and infected mice, peaking on day 9 p.i. (I, Fig. 4). 
LBP is principally produced in the liver, where its synthesis can be stimulated by 
IL-1β and IL-6 (Schumann et al., 1996).  Elevated LBP levels in serum have been 
described in septic patients (Blairon et al., 2003).  Mouse studies have emphasized the 
role of LBP in initiating the host response against the pathogen but also protecting 
animals against the toxic effects of LPS (Fierer et al., 2002; Jack et al., 1997; Knapp et 
al., 2003).  Lamping et al. have reported that acute phase concentration of LBP pro-
tects mice from the effects of LPS and gram-negative bacteria (Lamping et al., 1998).  
In light of that study, a comparable acute phase concentration of LBP was reached on 
day 9 in C. pneumoniae infected mice in the present study.     
5.1.2 Serum lipids  
We found no permanent effect of acute C. pneumoniae infection on serum lipids.  
Small differences were observed among experimental animal groups in triglycerides 
with the exeption of a transient significant elevation of VLDL triglycerides (I, Fig. 
3) in C. pneumoniae infected mice.   
In animals and humans, infection and inflammation induce a broad range of al-
terations in serum lipids as well as in enzymes involved in lipid metabolism 
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(Khovidhunkit et al., 2004).  Both bacterial and viral infections cause hypertriglyc-
eridemia in humans (Gallin et al., 1969; Grunfeld et al., 1992; Sammalkorpi et al.,
1988).  In animal studies, LPS administration is generally used to mimick infection.  
Subcutaneous or intraperitoneal LPS administration leads to hypertriglyceridemia in 
rabbits (Hirsch et al., 1964; Lequire et al., 1959), other rodents (Feingold et al.,
1993a; Feingold et al., 1992; Fiser et al., 1973; Gaal et al., 1984; Sakaguchi et al.,
1979; Scholl et al., 1984) and monkeys (Fiser et al., 1974).  Hypertriglyceridemia is 
characterized by increased VLDL (Hardardottir et al., 1995) due to either increased 
VLDL production or decreased VLDL clearance depending on the LPS dose used 
(Feingold et al., 1992).  Hypertriglyceridemia induced by LPS is detected 1-2 hours 
after administration, disappearing thereafter relatively rapidly.  Our study suggests a 
similar, transient elevation in triglycerides.  Since we did not further analyze the 
enzymes regulating triglyceride metabolism in the liver, the mechanism behind 
triglyceride elevation on hepatic level remained unanswerd.   
In agreement with other C. pneumoniae mouse studies (Aalto-Setälä et al.,
2001; Blessing et al., 2001; Erkkilä et al., 2004; Memon et al., 1997), C. pneumo-
niae caused no constant change in serum cholesterol levels.  In rodents, serum cho-
lesterol levels increase during LPS administration due to decreased cholesterol ca-
tabolism and increased hepatic cholesterol synthesis.  LPS administration increases 
hepatic de novo cholesterol synthesis by stimulating HMG-CoA reductase (Feingold
et al., 1993a; Feingold et al., 1995), with a concomitant decrease in the activity of 
squalene synthase, another enzyme downstream in the cholesterol synthesis pathway 
(Memon et al., 1997), resulting eventually in only a  small increase in hepatic cho-
lesterol synthesis and serum total cholesterol levels. 
Alterations in cholesterol as a consequence of infection differ strongly among 
species due to substantial differences in baseline cholesterol distribution between lipo-
proteins.  In rodents, the majority of their cholesterol is located in the HDL fraction 
and the minority in LDL, whereas in humans, the LDL fraction is generally most 
abundant.  In humans, infections generate a reduction in serum total cholesterol levels 
(Sammalkorpi et al., 1988; van Leeuwen et al., 2003).  Moreover, prolonged infection 
is associated with unfavourable cholesterol distribution (elevated LDL and decreased 
HDL), which has been observed in persons with serological evidence of C. pneumo-
niae infection, too (Laurila et al., 1997; Laurila et al., 1998; Murray et al., 1999).
5.1.3 PLTP, LCAT and HL activities 
As could be expected in light of the mild changes in serum lipids, C. pneumoniae
infection also resulted in minor changes in the enzyme activities regulating lipopro-
tein metabolism.  PLTP and HL were not affected by C. pneumoniae (I, Fig. 5B, C), 
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instead, in infected mice LCAT activity diminished almost 70 % from the baseline 
value on day 9 (I, Fig. 5A).   
There are few reports showing data on the effect of infection on serum PLTP ac-
tivity in mice.  In humans, PLTP activity is significantly increased in patients with a 
systemic inflammatory response (Barlage et al., 2001).  Contradictory to this, injec-
tion with a high LPS (50 μg/animal) dose causes a remarkable reduction in serum 
PLTP activity in C57BL/6 mice (Jiang et al., 1995).  Downregulation of PLTP re-
sulted in increased HDL phospholipids and HDL surface area (Jiang et al., 1995), 
and was believed to increase the LPS binding capacity of HDL (Ulevitch et al.,
1978).  In our study, C. pneumoniae infection was probably insufficiently robust to 
influence PLTP activity.   
Another essential enzyme involved in HDL metabolism is HL, which plays a 
role in both the conversion of IDL to LDL as well as in the formation of small 
spherical and preβ-HDL particles.  Decreased HL activity, seen in humans during 
the acute phase response (Grunfeld et al., 1991; Kwong et al., 1997; Levy et al.,
1993; Sammalkorpi et al., 1988), may therefore account for multiple alterations in 
plasma lipoproteins.  Although endotoxin administration decreases HL activity sig-
nificantly in rodents (Feingold et al., 1999; Kawakami et al., 1986), we could not 
demonstrate any effect of acute C. pneumoniae infection on HL.  Whether repeated 
C. pneumoniae infections affect HL activity or other lipolytic enzymes has not yet 
been investigated.   
LCAT activity was found to be substantially reduced after C. pneumoniae infec-
tion.  The effect of C. pneumoniae infection on LCAT has not been reported earlier.  
Other studies have demonstrated reduced LCAT activity after endotoxin administra-
tion in rodents (Ly et al., 1995).  The drop in LCAT activity leads to a declined con-
version of free cholesterol to cholesterol esters and thereby is responsible for impaired 
the cholesterol removal ability of acute phase HDL (Khovidhunkit et al., 2001).  
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5.2 Effect of pravastatin treatment on Chlamydia pneumoniae
infection, inflammation and serum lipids in NIH/S mice (II) 
5.2.1 Chlamydial culture from lung tissue, serum C. pneumoniae IgG 
antibodies and pulmonary inflammation 
Hydrophilic pravastatin accelerated the inflammatory response to C. pneumoniae
infection, but was not able to decrease the infection load in the lungs of NIH/S mice 
(II, Fig. 1).  Pravastatin treatment had no effect on the serum SAA levels of infected 
mice during a chow diet; SAA levels during high fat were not studied.  
Statins are known to possess anti-inflammatory effects in addition to their cho-
lesterol lowering capacity.  An antiproliferative effect of lovastatin during Salmo-
nella enterica serovar typhimurium infection has recently been reported (Catron et 
al., 2004).  This antimicrobial effect of statins is mediated by nonsterol mevalonate 
products (Catron et al., 2004; Diomede et al., 2001).  In the present study, pravas-
tatin treatment accelerated the pulmonary inflammatory response to C. pneumoniae
infection without any effect on chlamydial growth in the lungs or on the antibody 
response to infection.  However, we recently demonstrated under identical experi-
mental conditions that lipophilic simvastatin amplifies pulmonary inflammation, but 
also significantly decreases chlamydial counts in lung tissue in the early phase of 
infection (Erkkilä et al., 2005). 
There is one crucial difference between simvastatin and pravastatin that might pro-
vide an explanation for the diverse antichlamydial effect between these two statins.  
Chlamydiae have been shown to contain eukaryotic lipids, including cholesterol (Ziegler
et al., 1992).  A deficiency of cholesterol synthesis genes in the chlamydial genome 
(Kalman et al., 1999) makes Chlamydia dependent on host cell lipids.  Indeed, there is 
evidence of phospholipid trafficking from host cells to C. trachomatis (Hackstadt et al.,
1995).  Lipophilic statins (e.g. simvastatin) are taken up by passive diffusion into a broad 
range of cells, while hydrophilic statins (e.g. pravastatin) penetrate the cell by the so-
dium-independent bile acid transporter present only in hepatocytes (Ziegler et al., 1992).  
Therefore, simvastatin may perturb intracellular cholesterol metabolism, which in turn 
hampers C. pneumoniae growth in alveolar macrophages. 
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5.2.2 Serum lipids  
As a consequence of high fat feeding, serum total cholesterol levels increased sig-
nificantly.  Size-exclusion chromatography analysis indicated that the cholesterol 
increment was localized majorily in HDL with some elevation in apo B-containing 
lipoproteins (Fig. 6).   
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Serum triglycerides but not cholesterol were increased by the pravastatin treat-
ment throughout the follow-up period during high fat (II, Table 1.).  Similarly, 
triglycerides were consistently higher by pravastatin in C. pneumoniae infected mice 
during high fat.    
The triglyceride-increasing effect by pravastatin is a contradictory observation 
since in humans statins decrease triglycerides as well as total cholesterol, especially 
Fig. 6. Cholesterol distribution among NIH/S mice lipoproteins. Cholesterol 
distribution   between lipoproteins in NIH/S control mice on regular chow 
(closed circle) and high fat diet (open circle) was analyzed by using a Superose 
6 HR gel filtration column.  The column was equilibrated with phosphate buff-
ered saline (PBS), pH 7.4, and 200 μl of serum sample was applied to the col-
umn.  The flow rate was 0.25 ml/min and 0.5 ml fractions were collected and 
used for cholesterol measurement.
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LDL (Conde et al., 1999; Streja et al., 2002).  We have no explanation for this diet-
dependent response in triglycerides during pravastatin and C. pneumoniae.  Gener-
ally, infection studies have been carried out in genetically modified, i.e. more “hu-
manized” mice, such as heterozygous LDL receptor (LDLR) +/- and apolipoprotein 
E (apoE) +/- mouse strains.  These mice are more sensitive to dietary lipids, and 
significant changes in lipoprotein profiles during infection could thus be expected.  
Our data highlight the importance of using a suitable animal model to study 
lipid/lipoprotein changes during infection.   
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5.3 Novel enzymeimmunoassay utilizing lipopolysaccharide 
binding protein as a capture molecule for the measurement of 
chlamydial lipopolysaccharide in serum (III) 
5.3.1 Optimization of EIA conditions 
D e t e r g e n t s  
In serum, LPS can be found in several compartments, incorporated into lipoprotein 
membranes, complexed with immunoglobulins (especially IgM), associated with 
carrier or receptor proteins (LBP, mCD14, sCD14) or as a free micellar form.  To 
optimize LPS dissociation conditions, we tested a set of detergents with different 
physicochemical natures.  Among them, sodium cholate, Brij 35 and octylglucoside 
(in PBS) were found to be the most effective (Fig. 7). 
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Fig. 7.  The ability of detergents to solubilize C. pneumoniae LPS. Serum samples 
spiked with C. pneumoniae K6 elementary bodies (EBs) were examined by using 
96-well microtiter plates coated with a catching monoclonal anti-
lipopolysaccharide-binding protein (mouse anti-LBP) antibody (0.5 μg/well).  
Plates were first incubated with human LBP (1 μg/ml) for one hour at +37 ºC.  Af-
ter washing, serum containing C. pneumoniae K6 EBs in the presence of different 
detergents was added and incubated for one hour at +37 ºC.   The plates were 
washed, and a biotinylated mouse monoclonal anti-cLPS antibody (Spriggs et al.)
was used for detection. 
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Sodium cholate, Brij 35 and octylglucoside were further studied at 0.1 % and 
0.5 % concentrations.  A better resolution with each detergent was obtained at a 0.1 
% concentration.  Based on the sensitivity at low cLPS concentrations, a 0.1 % non-
ionic octylglucoside was chosen for the sample pre-treatment. 
Due to lipophilic and hydrophilic moieties, LPS exists in several aggregated 
forms in aqueous preparations and, most crucially, is in the biologically active state 
as a monomer (Mukerjee et al., 1999).  For this purpose, detergents are indispensa-
ble in solubilising LPS from a variety of serum complexes.  In our assay, we used 
LBP as a natural binding agent for the lipid A part of the LPS molecule and mono-
clonal antibodies against a KDO-oligosaccharide epitope of LPS.  Under these con-
ditions, the detergent used in an EIA assay must preserve the functional and struc-
tural properties of LPS.  We are aware that octylgucoside at a 0.1 % concentration is 
far below the critical micelle concentration (CMC) determined for this detergent 
(Neugebauer, 1990).  Concerning membrane proteins, operating below CMC has 
been suggested to limit the concentration range at which solubilization progresses 
(le Maire et al., 2000).  However, experiments with 0.5 % octylglucoside, very close 
to its CMC, yielded a poor response in the LPS-EIA assay.  On the other hand, oc-
tylglucoside at concentrations above CMC were not studied. 
C o a t i n g  a n t i b o d y  a n d  b l o c k i n g  b u f f e r  
Mouse moclonal anti-LPS antibody clone 6703 reacted with Salmonella minnesota
re-LPS.  Mab clones 6701 and 6709 were included for further analysis.  Mab clone 
6709 showed a more efficient cLPS binding capacity than clone 6701.  The optimum 
LPS response was achieved at a 0.5 μg/ml coating antibody concentration.  To avoid 
non-specific binding, the EIA response for cLPS with the 6709 antibody was then 
investigated in the presence of various blocking buffers.  The most optimal antigen-
antibody reaction and minimal background was reached by blocking plates with 
PBS supplemented with 0.2 % defatted milk. 
In our EIA assay, Chlamydia-specificity was determined by a using monoclonal 
anti-cLPS antibody, clone 6709, as a trapping agent.  This antibody showed no reac-
tivity with Bartonella henselae or Simkania negevensis, which have previously been 
demonstrated to either cross-react (Maurin et al., 1997) or display structural similar-
ity with Chlamydia (Lieberman et al., 2002).  Moreover, the capture antibody did 
not bind S. minnesota Re-LPS, structurally and immunologically related to cLPS 
(Brade et al., 1985; Brade et al., 1986; Nurminen et al., 1984).  Hence, coating anti-
body 6709 was Chlamydia-specific and recognizes either the disaccharide (α−KDO 
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(2?8)-α-KDO) or trisaccharide (α-KDO-(2?8)-α-KDO (2?4)-α-KDO) part of 
KDO in the cLPS structure (Brade et al., 1994).  Finally, since cLPS is a group-
specific antigen in Chlamydia (Dhir et al., 1972), our EIA method can be used for 
measurement of chlamydial LPS without discrimination between chlamydial spe-
cies.  Nevertheless, it is evident that in genital infections, the amount of LPS in the 
lesions is too low to be detectable in serum. However, in ascending complications of 
C. trachomatis infections, such as pelvic inflammatory disease and perihepatitis, 
cLPS could be present in serum (Puolakkainen et al., 1990) and give a positive re-
sult in the present cLPS-EIA test.  The current EIA would be most suitable for diag-
nosis of chronic C. pneumoniae infection in the lungs or in the vasculature.  These 
diseases are common in the elderly, in which C. trachomatis infections are rare.  Use 
of cLPS-EIA in the diagnosis of acute infections might also be possible. 
O t h e r  E I A  c o m p o n e n t s  
Optimal dilutions of LBP, a detection antibody (a-LBP) as well as an enzyme-
labeled secondary antibody (GAR-HRP) were defined by checkerboard titration.  
The maximum EIA signal for cLPS was achieved with the following combination: 
LBP 1 μg/ml, polyclonal a-LBP 1:500, both diluted in 0.1 % Tween 20 and GAR-
HRP 1:10 000 in Tween 20-PBS supplemented with 10 % fetal bovine serum (FBS).   
Solubilization and monomerization of cLPS from all serum complexes is a pre-
requisite for the reliable quantitation of LPS by the EIA method.  The novelty to the 
present assay comes from the utilization of a natural LPS-binding protein, LBP, as 
an LPS capture agent before trapping LPS by a solid phase monoclonal antibody.  
Given that the LBP concentration in normal human serum is about 5-10 μg/ml, we 
used a huge excess of LBP (1 μg/ml of LBP for sera diluted 1:50) in the assay.  
Since a lower LBP concentration (0.5 μg/ml) resulted in a weaker response, signifi-
cant excess may be necessary to dissolve LPS from complex forms in serum.    
S t a n d a r d i z a t i o n  o f  t h e  a s s a y      
In order to standardize the EIA assay, cLPS was purified with the phenol/chloroform 
extraction method (Rund et al., 1999) from a C. pneumoniae K6 isolate.  Purified 
cLPS was analyzed by 15 % SDS-PAGE and visualized by silver staining (Lee et 
al., 1989).  cLPS displayed a single, 10-15 kDa band (III, Fig. 2).  Approximately 
the same size for cLPS has been reported earlier (Nurminen et al., 1983; Nurminen
et al., 1984).  A KDO-thiobarbituric assay was used for measuring the cLPS concen-
tration (Waravdekar et al., 1959), which was 84,1 μg/ml in the extract.   When EIA 
was standardized with purified cLPS, a concentration-dependent response was ob-
tained (III, Fig. 3).    
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F i n a l  p r o c e d u r e  a n d  a p p l i c a t i o n  o f  t h e  m e t h o d  f o r  
c l i n i c a l  m a t e r i a l  
After optimizing all EIA conditions, the final procedure described in Chapter 4.2.3 
(page 41) was attained and used for clinical applications.  The EIA consisted of four 
incubation steps and finally, a relatively large immunological complex was built (III, 
Fig. 1).  Nevertheless, multiple incubation steps are known to improve EIA sensitiv-
ity and therefore, a reduction in the number of incubation steps was not required.  
This newly developed EIA was first applied to serum cLPS quantification from 102 
ACS patients and their age- and sex-matched controls (III, Table 1).  The criteria for 
ACS, originally described elsewhere (Sinisalo et al., 2002), are briefly described in 
Chapter 4.1.2.  Significantly higher cLPS prevalence and concentrations were found 
in ACS patients compared to healthy controls (III, Table 1; P < 0.001 for both).  
Analysis within genders revealed that the difference in cLPS positivity among 
women was not significantly different although the cLPS concentration was still 
significantly higher in ACS patients than in the controls (III, Table 1).  This result 
could be related to the small number of women studied.  Analysis of the whole data 
with an ROC curve, commonly used in evaluating the diagnostic value of the 
method, indicated nearly 80 % sensitivity and specificity for the cLPS-EIA to sepa-
rate ACS patients from their control subjects [III, Fig. 4, area under the curve (AUC) 
value 0.797].   
The diagnosis of chronic C. pneumoniae infection is problematic.  After an acute 
infection, IgM and IgA antibodies usually disappear in some months, while C. pneu-
moniae IgG antibodies may remain elevated for years (Domeika et al., 1997; 
Paldanius et al., 2005) and their presence can therefore be considered only a marker of 
present or past exposure to C. pneumoniae.  Because of their shorter biological half-
life, IgA antibodies are considered a more reliable marker of chronic infections 
(Saikku, 1992).  PCR can be used for the detection of C. pneumoniae DNA in circulat-
ing white blood cells, but this approach requires special techniques not available in all 
laboratories.  In addition, the detection of C. pneumoniae by PCR seems to lack sensi-
tivity and needs further optimization (Smieja et al., 2002).  Overall, the need for direct 
diagnostic method for the chronic C. pneumoniae infection has grown.
In the present study, we developed a specific and sensitive EIA method for the 
quantification of cLPS utilizing a novel methodological approach.  Since chronic C. 
pneumoniae infection has been strongly associated with cardiovascular diseases, the 
EIA was first applied to analyze cLPS levels among acute coronary syndrome pa-
tients and their controls.  Serum cLPS was found more often and cLPS levels were 
also significantly higher in the ACS patients compared to healthy controls.  Since 
the patient sera were collected after the cardiac event, large amounts of cLPS might 
have been liberated into circulation at the time of tissue damage.  Supporting this, 
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earlier studies on cLPS immune complexes have suggested the formation of cLPS 
containing immune-complexes after a myocardial infarction in the presence of cLPS 
excess (Leinonen et al., 1990).  The evaluation of diagnostic efficacy and the clini-
cal usefulness of the cLPS-EIA method with an ROC curve revealed high specificity 
and sensitivity to discriminate between ACS patients and controls.  Further studies 
are needed to illuminate whether circulating cLPS is usable as a marker of increased 
risk for cardiac events.
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5.4 Chlamydial lipopolysaccharide is present in serum during 
acute coronary syndrome and correlates with CRP levels (IV) 
Markers of C. pneumoniae infection (C. pneumoniae IgA and cLPS levels) and 
hsCRP concentration were analysed in sera collected from ACS patients during a 
one-year follow-up period (for sample collection, see Chapter 4.1.2).  The clinical 
history of the patients revealed hypertension, diabetes, and hypercholesterolemia in 
42 %, 19 %, and 77 % of the subjects, respectively.  In addition, 41 % of the patients 
were under statin therapy.  Serum total cholesterol and LDL cholesterol concentra-
tions were not significantly elevated (IV, Table 1).   Acute myocardial infarctions 
(AMI) caused hospitalization in 71 % of the patients, the rest (29 %) entered hospi-
tal due to unstable angina (UA).  The use of statins did not significantly affect serum 
cLPS or hsCRP levels (IV, Table 2).  Except for hsCRP, some sporadic correlations 
of different clinical and laboratory parameters with cLPS were detected (IV, Table 
2). Serum hsCRP and cLPS levels correlated significantly in the patients throughout 
the one-year follow-up period (IV, Fig 1), and were significantly elevated in AMI 
patients at the time of hospitalization when compared to those in UA patients.  The 
highest hsCRP and cLPS levels were observed within 48 hours after the acute event 
(IV, Fig 1).  Both hsCRP and cLPS levels started to decrease immediately after the 
ACS event till the end of the follow-up (IV, Fig. 1). However, C. pneumoniae IgA 
antibodies, detected in 53 % of the ACS patients, did not decline in parallel with 
cLPS during the follow-up (Fig. 8).  Compared to control subjects, C. pneumoniae
antibodies and cLPS levels were significantly elevated.  It is well known that C. 
pneumoniae antibody prevalence increases with age (Grayston et al., 1990; Ham-
merschlag, 2002).  However, although the controls were not fully age-matched 
(mean ages of 64 and 57 years in the patients and controls, respectively), the small 
difference in age had no significant effects on the results. 
LPS is one of the major components in the C. pneumoniae outer membrane. 
Chlamydial LPS is capable of inducing the inflammatory cytokine response even 
though its endotoxin activity has been shown to be significantly lower than that of 
enterobacterial LPS (Ingalls et al., 1995).  Despite its low potency to induce cyto-
kine secretion, LPS seems to be the main chlamydial component to induce macro-
phage transformation to cholesterol-containing foam cells (Kalayoglu et al., 1998a).  
Chlamydial LPS is abundantly detectable in inoculated arteries over one month post 
C. pneumoniae infection in an ex vivo culture model (Poppert et al., 2005).  Fur-
thermore, E. coli LPS has been demonstrated to stimulate CRP production in vitro
(Calabro et al., 2003).  In the present study, a very significant correlation between 
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cLPS and CRP levels was demonstrated in the sera obtained from patients with 
ACS.  After the coronary event, both cLPS and CRP levels decreased, and the corre-
lation remained significant during the entire follow-up period.  These results 
strongly suggest the liberation of cLPS from the damaged C. pneumoniae-infected
arterial tissue site during an acute coronary event, which leads to dose-dependent 
production of CRP.  Interestingly, C. pneumoniae IgA antibody titers stayed at a 
stable level during the follow-up (Fig. 8) and hence, did not reflect the actual behav-
ior of the infection. 
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Fig. 8.  Serum C. pneumoniae IgA antibody (open circle) and cLPS (closed circle) 
levels in ACS patients during the follow-up time. 
Some earlier studies also postulate that high chlamydial LPS levels are present 
in circulation after an acute coronary event: acute myocardial infarction (AMI) pa-
tients show an antibody response to chlamydial LPS (Kiss et al., 2001; Saikku et al.,
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1988), albeit IgA antibodies against C. pneumoniae structural proteins remain con-
stantly elevated (Saikku et al., 1988).  Consistent with these serological findings, the 
highest cLPS levels in ACS patients were observed during the acute event, suggest-
ing the antigen is released from the ruptured lesion area.  Reflecting the severity of 
the acute event, serum cLPS was significantly higher in patients with AMI as com-
pared to those with UA.  In both patient groups, cLPS levels decreased remarkably 
within one week of the event.  Supporting this, previous observations demonstrate 
that in the acute phase of AMI, patients have a serum cLPS excess, which disappears 
within one month (Leinonen et al., 1990).  These data suggest relatively rapid clear-
ance of cLPS from circulation after the AMI and agrees with the present finding, 
which shows decreased cLPS levels as early as one week after the ACS.  Whether 
the combination of increased cLPS and hsCRP could be used as a risk marker for 
cardiac events and in monitoring the risk during intervention trials remains an inter-
esting open question and needs further evaluation.  Recent antibiotic intervention 
trials have shown no effect on C. pneumoniae infection (Anderson, 2005; Grayston
et al., 2005), suggesting that chronic C. pneumoniae infection can not be eradicated 
by monotherapy only, documented also in animal models (Rothstein et al., 2001; 
Törmakangas et al., 2004).  Therefore, new generation antibiotics or relevant drug 
combinations may be needed to eliminate C. pneumoniae from the lesions and retard 
the progression of atherosclerosis.    
The present data suggest that C. pneumoniae, being present in the lesions, may 
be involved in plaque rupture.  The combination of hsCRP and cLPS quantitation in 
subjects might be a useful tool in the evaluation of the risk for cardiovascular events.   
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6 SUMMARY AND CONCLUSIONS 
The first part of the study investigated the modulatory effects of acute C. pneumo-
niae infection alone and combined with statin treatment on infection, inflammation 
and lipid metabolism using an NIH/S mouse model.  The focus in the latter part of 
the thesis was on chronic C. pneumoniae infection in human subjects.  A new diag-
nostic method for C. pneumoniae was developed and the applicability of the method 
for analyzing clinical material was examined. 
Although endotoxin administration in mice and in other rodents is widely used 
to mimic infection and results in more robust changes in lipid metabolism, intranasal 
infection with C. pneumoniae is probably a more physiologically relevant way to 
study the consequences of infection.  Very mild changes in serum lipid metabolism 
were detected after a single C. pneumoniae inoculation in NIH/S mice with a tran-
sient increase in triglycerides and a decrease in LCAT activity.  However, if these 
changes are prolonged during a chronic state, they may impair lipid metabolism and 
alter lipid distribution towards a pro-atherogenic profile.  Regarding the effects of C. 
pneumoniae infection on serum lipid levels, other animal models with a lipid status 
similar to that detected in humans would be more functional. 
The pulmonary inflammatory response to C. pneumoniae infection was acceler-
ated by pravastatin treament compared to untreated control mice. However, no effect 
on C. pneumoniae growth could be demonstrated. Pravastatin induced unexpected 
changes in serum lipid levels during high fat.  In uninfected and C. pneumoniae
infected NIH/S mice, a significant increase in serum triglycerides was observed.  A 
favourable, antiatherogenic lipid profile with the majority of the cholesterol in the 
HDL fraction may be one reason for the minor effect of pravastatin on cholesterol in 
NIH/S mice.  Because mice are HDL mammals, it would be practical to study other 
animal models to discover whether pravastatin or other statins possess lipid-
lowering or anti-inflammatory effects during C. pneumoniae infection.   
A novel diagnostic method for C. pneumoniae infection was developed and ap-
plied to the serum material collected from ACS patients and their controls.  The 
choice of detergent and optimization of all assay conditions yielded a specific and 
sensitive EIA method for cLPS quantification.  The crucial point and novel approach 
was the use of LBP in LPS trapping from serum complexes.  We found a signifi-
cantly higher cLPS concentration and prevalence in ACS patients than in their con-
trols.  Evaluation of the method indicated as high as 80 % specificity and sensitivity 
in discriminating patients and controls in this setup.  The correlation between hsCRP 
and cLPS suggested cLPS to be responsible for the inflammatory response.  After 
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the acute coronary event, cLPS levels started to decrease within one week indicating 
i) the contribution of cLPS to an acute coronary event and ii) relatively rapid cLPS 
metabolism after ACS.  Indicating poor diagnostic value, serum IgA antibodies were 
elevated in 53 % of the patients and remaining constant throughout the follow-up.  
The suitability of cLPS quantitation by the novel EIA method in other clinical and 
physiological settings remains a future challenge.  Whether the combination of 
hsCRP and cLPS quantitation is a useful tool in the evaluation of the risk for cardio-
vascular events should be verified in future studies.   
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